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Abstract 
 
Important for the regulation of bodily glucose levels and within the fight-or-flight 
response, the glucocorticoid receptor has become an interesting pharmaceutical target, 
with the discovery that both natural and synthetic glucocorticoids induce a significant 
anti-inflammatory effect.  Current research focuses on the synthesis and identification 
of novel selective glucocorticoid receptor modulators, which lack the debilitating side 
effects associated with these drugs. Building upon the work of previously successful 
glucocorticoid modulators, pyrazole 2 is the target for this work.  The first part of this 
thesis describes investigations into the synthesis of the Wieland-Miescher ketone 
(WMK) analogue 1; an important intermediate in the prospective synthesis of pyrazole 
2.  The traditional route towards WMK analogues via a Robinson annulation proved to 
be unsuccessful, with a range of catalysts trialed for the key Robinson annulation step 
and with difficulties arising from the synthesis of the key pyran-3,5-dione precursor.  
The second route proved to be more successful with the methoxy-protected WMK being 
afforded, via a 6-step route with a key Birch reduction step. 
 
 
Scheme 1 
 
α-Aminosulfonamides are a relatively unknown functionality, which possess the ability 
to mimic natural amino acids and behave as peptidomimetics.  Previous literature has 
described this advantageous functional group as both synthetically challenging and an 
unstable moiety. Employing novel radical reaction conditions developed within the 
Wilden group, a selection of both the unusual α-aminosulfonamide and the more readily 
available β-aminosulfonamide have been synthesised in significant yields. 
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1. The Glucocorticoid Receptor & Glucocorticoids 
 
1.1   The Glucocorticoid Receptor 
 
As a member of the nuclear hormone receptor family, the glucocorticoid receptor, along 
with its siblings, the mineralcorticoid, progesterone, androgen and estrogen receptors, make 
interesting pharmacological targets due to their ligand dependent activity.1 The endogenous 
steroid hormones of each of these receptors all share an almost identical core steroid 
skeleton, with the receptors themselves sharing over 50% of their amino acid sequences.2 
These similarities allow the interaction of agonists with alternative members of the family 
causing significant problems in the development of drug candidates.  Glucocorticoids (GC) 
in particular display high levels of interaction with the mineralcorticoid receptor (MR) and 
the GC drugs dexamethasone 3 and prednisolone 4 can also be used as MR agonists.3-5 
However, cross reactivity is one of the causes of a number of the debilitating side effects 
that are associated with the prolonged use of GCs.  Unsurprisingly this is not a problem 
unique to Glucocorticoid Receptor (GR) and its ligands but occurs with all nuclear hormone 
receptors.  A notable example is the progesterone antagonist, mifepristone 5, which 
displays promise as a clinically useful contraceptive but its overt GR antagonism 
compromises its utility.6  
 
 
Figure 1 
 
Unlike other members of the family, the GR is located within almost every cell in the 
body5 and in the absence of a ligand, resides in the cell’s cytoplasm surrounded by 
chaperone proteins.2,7 Consisting of 777 amino acids,8  the GR is a modular protein with 
3 domains, a C-terminal ligand binding domain, a DNA binding domain and an N-
terminal domain.9  
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Figure 2: Glucocorticoid Receptor Modular Structure showing the associated functions with each 
domain.8  
 
As expected, the ligand-binding domain is the region where acceptable ligands bind to 
the receptor, consisting of 12 helices with 4 β strands, which fold into a three-layered 
helical structure, creating a hydrophobic pocket for ligand bindings.2,9 The central DNA 
binding domain is responsible for recognising the target sequences within DNA. 
Thereby causing the dimerisation of the GR-GC complex and subsequent binding to 
specific sequences within the promoter region of the target genes.10 Structurally, this 
domain contains two distinct zinc fingers, which are critical for receptor dimerisation 
and unique for the nuclear hormone receptors, setting them apart from other DNA 
binding proteins.9,11 The role of the N-terminal domain is less significant than the other 
two but is important for activation and both co-factor and basal transcription factor 
interactions.8  
 
1.2   Cortisol & Synthetic Glucocorticoid Drugs 
 
The endogenous glucocorticoid, cortisol 6 (fig. 3), enables an organism to respond to 
stress, be it physical or emotional.5,8 Synthesised in the adrenal gland, cortisol is 
involved in glucose regulation in the blood, as well as fat and protein metabolism and 
involvement in the body’s growth and reproductive processes.5  
 
The “spectacular” anti-inflammatory effect of glucocorticoids was first observed in the 
1940s when the cortisol derivative, cortisone 7 (fig. 3), was first isolated and 
administered to a rheumatoid arthritis sufferer by chemist Edward Kendall and 
physician Philip Hench.12 Cortisone was hailed as a “wonder drug” in the treatment of 
inflammatory conditions and this work saw both Kendall and Hench awarded the 1950 
Nobel Prize for Medicine.12 However, recent research has shown that cortisone is 
inactive for GR and is in fact a pro-drug, which is metabolised to give cortisol as the 
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active molecule.12 It was not long after its launch that the long-term detrimental side 
effects of cortisone were revealed.   
 
 
Figure 3 
 
Synthetic glucocorticoids, dexamethasone 3 and prednisolone 4 (fig. 4) were identified 
as having a similar beneficial anti-inflammatory profile to cortisone but with slightly 
reduced side effects. They have become the glucocorticoids of choice to treat a range of 
inflammatory diseases, including asthma, allergic rhinitis and rheumatoid arthritis. In 
2010, it was estimated that over 50 % of patients suffering from rheumatoid arthritis 
were being treated with glucocorticoids more or less continuously13 and these first 
synthetic glucocorticoids are still the main treatment of conditions involving 
inflammatory processes.9 
 
 
Figure 4 
 
However a series of wide-ranging and debilitating side effects, osteoporosis, muscle and 
skin atrophy, hypertension and glaucoma, hamper extensive prolonged use of these 
drugs.4,14-16 A number of these side effects are due to cross reactivity with other 
receptors in the nuclear hormone family, notably the mineralcorticoid receptor, which 
dexamethasone 3 and prednisolone 4 both display agonism for and may contribute to 
the hypertensive side effects.9 Another cause of these side effects is also due to the 
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upregulation and transcription of metabolic and endocrine genes.17 This upregulation is 
controlled by the mechanism of action by the GC upon binding to the receptor and it is 
known as transactivation.   
 
1.3   Transactivation & Transrepression 
 
In the absence of a ligand, the GR is located in the cell’s cytoplasm and is surrounded 
by a large complex of heat-shock proteins (HSP), which bind to the receptor and 
prevent interaction with DNA.18 The introduction and binding of a ligand causes a 
conformational change in the HSP complex and the GR dissociates from its chaperones, 
exposing the nuclear localisation signals, which encourage translocation to the cell’s 
nucleus.17,18 Within the nucleus, the GR-ligand complex will bind to the palindromic 
sequence of glucocorticoid response elements (GRE), which initiate the transcription of 
genes and consequently the synthesis of proteins.5,18 This mechanism is known as 
transactivation and results in the transcription of the metabolic and endocrine genes. 
 
An alternative mechanism of the GR-GC complex involves a conformational change, 
which does not allow binding to DNA in the nucleus but instead exists as a monomer.17 
This change in conformation creates an affinity for the complex to bind to the 
transcription factors, NF-κB and AP-1, causing the inhibition of pro-inflammatory 
cytokines TNFα and IL-6.14 It is this inhibition that causes the advantageous anti-
inflammatory effects of glucocorticoid therapy, while the DNA interacting 
transactivation mechanism is responsible for the side-effects associated with 
glucocorticoids.  
 
In light of this clear separation between the mechanisms of the beneficial anti-
inflammatory effects and the side effects, the possibility of designing suitable 
compounds, which are selective for transrepression over transactivation, has been 
suggested.  Studies have shown that the GR is essential for life with GR deficient mice 
dying shortly after birth. Mice possessing modified GRs, which prevent dimerisation 
and DNA binding, have displayed reduced levels of transactivation. However a 
significant level of transrepression activity has been maintained, thereby supporting the 
theory that these two mechanisms can potentially be separated in the human GR by an 
appropriate ligand.4,19  
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1.4   Selective Glucocorticoid Modulators 
 
Over the decades, there has been much research into the identification of potential 
alternatives to the established glucocorticoid drugs.  However since observations have 
been made regarding the mechanism of action, which separates the beneficial and 
adverse effects of these drugs, attention has been drawn to identification of selective 
ligands for the GR. Thereby enabling the prolonged use of these drugs and the potential 
to increase the patient’s quality of life. 
 
1.4.1   Steroidal Selective Glucocorticoid Modulators 
 
Historically, the body’s glucocorticoid, cortisol 6 (fig. 3) has been used as a starting 
point for exploring potential beneficial modifications.  Interestingly, the two 
blockbuster glucocorticoid drugs, dexamethasone and prednisolone, have only minor 
differences to cortisol, which include an additional alkene bond in the A ring and the 
introduction of a fluorine atom and methyl group in dexamethasone.  As such, it has 
been a natural progression for researchers to focus on modifications to the steroidal 
skeleton and much of the focus has been on appendages to skeleton’s D ring.15,20,21 
Interestingly and significantly for this work, the introduction of a pyrazole motif 
adjacent to the steroid’s A ring to afford cortivazol 8 (fig. 5), as a potent glucocorticoid 
which rivals dexamethasone.22,23  
 
 
Figure 5 
 
One success story which has seen a compound make it to market, is that of fluticasone 
Furoate (FF) 10 and its sister compound fluticasone propionate (FP) 9 (fig. 6), topical 
intranasal glucocorticoids used for treatment against seasonal and perennial allergic 
rhinitis, displaying the coveted once-daily efficacy.24 With the propionate ester 9 
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released first in 2012 and the furoate ester 10 in 2014, both compounds incorporate a 
17β - fluoromethylthioester moiety instead of the hydroxyl seen in cortisol and 
dexamethasone 3, as well as the introduction of two fluorine atoms in the B-ring. The 
important structural change in these compounds was the introduction of the ester 
functionality instead of the hydroxyl in the parent steroid. As it will be seen in this 
example and subsequent studies, the GR ligand-binging domain displays a high level of 
flexibility due to its accommodation of a number of different structures and 
functionality.  These fluticasone esters have highlighted a previously undocumented 
pocket within the ligand-binding domain, the 17α pocket. The ability of the esters to 
access this pocket resulted in compounds, displaying a high GR binding affinity with 
the furoate ester (FF) 10 showing the highest binding affinity reported to date.24  
 
 
Figure 6 
 
X-ray crystal structures of these ligands bonded to the glucocorticoid receptor binding 
pocket confirm the propionate & furoate esters are encompassed by the lipophilic 17α 
pocket.24 While the propionate ester only shows a partial fulfillment of the pocket, the 
furoate ester shows a complete fulfillment.  Being esters rather than a hydroxyl, these 
compounds do not allow for the hydrogen bond between the 17α hydroxyl group and 
Gln642 observed in dexamethasone but instead are compensated by favourable van der 
Waals interactions.24 It is thought that alongside the favourable van der Waals 
interactions, the complete fulfillment of the 17α pocket by the furoate ester moiety, is 
the reason for the high binding affinity for this compound for the GR.   
 
Alongside this work, researchers also explored the X-ray crystal structures of other 
steroidal ligands bound to the glucocorticoid receptor.  In a screen of dexamethasone 3, 
FF 10 and deacylcortivazol (DAC) 11 (fig. 7) showed that dexamethasone 3 occupied 
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the smallest binding pocket within the ligand-binding domain of the GR, while FF and 
DAC extended it in two directions.25 The extension of FF into the aforementioned 17α 
pocket and the pyrazole unit appended to the A ring in DAC did not affect the position 
of helix 12, which is associated with the functionality of nuclear receptors.  The 
flexibility of the binding pocket in the glucocorticoid receptor suggests the potential for 
further extensions to the steroid skeleton and also the accommodation of non-steroidal 
structures.   
 
 
Figure 7 
 
Building on from the success of the fluticasone esters as GR agonists, researchers at 
Merck investigated the tolerance of the 17α pocket with the use of the carbamate 
functionality.  Derived from betamethasone 12 (fig. 8), the resulting carbamate 
analogues showed a good binding affinity for GR, with some examples displaying the 
same or better affinity than prednisolone. The ethyl analogue 13 (fig. 8) showed 
exceptional affinity for the GR with an IC50 = 5.1 nM when compared to prednisolone 
(IC50 = 13.8 nM) and also displayed a desirable dissociated profile against the 
progesterone receptor.  Increasing the alkyl chain length leads to compounds being only 
partial agonists with non-dissociated profiles, while branched alkyls and the 
introduction of further polarity led to a decrease in affinity for GR.21  
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Figure 8 
 
1.4.2   Non-Steroidal Selective Glucocorticoid Modulators 
 
With steroidal structures being large and to a degree possessing a difficult synthesis, the 
evident flexibility seen with the GR and the ‘structural diversity’ offered by non-
steroidal ligands have drawn attention to the potential of non-steroidal ligands to afford 
selective glucocorticoids.26  
 
Recent literature has highlighted a number of non-steroidal compounds, which have 
been identified as GR ligands with a varying degree of both potency and selectivity.27,28 
A large variety of structures have been reported, with the development of improvements 
to notable ligands being chronicled.  
 
Alongside the success GSK experienced with their fluticasone esters 9 and 10 (fig. 6), 
research continued into the search for the holy grail of GR ligands, a selective and 
potent oral drug and their direction turned towards non-steroidal compounds based 
around tetrahydronaphthalene (THN) structures 14 (fig. 9).  
 
 
Figure 9 
 
When R1 is set as a 5-aminobenzoxainone moiety 15 (fig. 9), the resulting series of 
compounds showed that GR agonism is “balanced on a knife edge” with the nature of R 
acting as an agonist trigger, modifying the behaviour of the ligand to switch between 
O
HO
H
F
OH
H
O OH
Betamethasone
12
O
HO
H
F
O
H
O OH
13
O
H
N
OHF3C HN
OR
15
O
NH
O
OHF3C HN
OR
14
R1
 
1.   The Glucocorticoid Receptor & Glucocorticoids
 
  9 
agonism and antagonism.  When R = H the ligand displays an antagonist profile but by 
making the small change to an ethyl group dramatically changes the ligand into a full 
agonist.29 
 
In addition to the controllable agonist/antagonist profile, a number of these compounds 
showed selectivity for transrepression over transactivation assays and a 100-fold 
increase in potency for the GR over other members of the receptor family, displaying 
the desired selective profile.29 However the 5-aminobenzoxainone moiety severely 
limits the chemistry of the molecule and alongside indications from in vitro studies on 
liver samples that this group could be readily metabolised, the compounds described so 
far were not considered compatible as an oral therapy.30  
 
 
Figure 10 
 
As an alternative to the benzoxainone moiety, a variety of normal and reverse amides 
and sulfonamides were surveyed with the reverse amide pyrazole moiety displaying a 
promising profile. The 5-methylpyrazole analogue 16 (fig. 10) is a potent binder for the 
GR displaying partial TR agonism and no TA agonism.  Replacement of the 5-methyl 
for a 5-amino group in 17, which, through a hydrogen bonding network, forms a 6–
membered ring (fig. 11), transforms this compound into to a full agonist for TR with a 
10-fold increase in potency.  However this compound is also a full agonist for the TA 
assays.  Although this series of compounds displayed an outstanding selectivity for GR 
over other receptors in the family and are potent agonists, they lack TR/TA selectivity 
resulting in a disappointing series.30  
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Figure 11 
 
With research concentrating on the search for oral drugs, it was thought necessary to 
replace the THN moiety with an aryl group, which gives a more appropriate 
pharmokinetic profile for an oral therapy.  This aryl group is designed to occupy the 
same hydrophobic pocket as the ester groups in FP and FF (fig. 6), the 17α pocket. By 
linking the aryl group to the right hand side of the molecule seen in 17 (fig. 11) with an 
N-substituted amide, which would provide an agonist trigger in the form of N-
alkylation, giving rise to pyrazole 18.  A variety of substitution patterns were trialed on 
the aryl ring with polar substituents resulting in a reduced potency, while a di-ortho 
substitution pattern proved to enhance potency.  All compounds showed excellent 
selectivity for the GR over other receptors in the family. Variations in the trigger group 
lead to an increase in potency with an ethyl group being the most potent and able to turn 
the powerful 2,6-substitution pattern from a partial agonist to a full agonist in 
compound 19 (fig. 12).  This series of molecules has not produced a number of potent 
agonists with oral drug-like properties; however none of these ligands displayed a 
dissociated TR/TA profile.31  
 
 
Figure 12 
 
As previously stated the 5-aminopyrazole and the neighbouring amide seen in these 
compounds forms a 6-membered ring through hydrogen bonding, which dramatically 
increased its potency when compared to the analogous methyl.  An increased activity is 
observed with the replacement of this hydrogen bond with a bicyclic indazole system 20 
(fig. 13).  Alongside the optimisation of the N-alkyl agonist trigger for the most potent 
ethyl, resulted in the discovery of compound 20, which had a similar level of TR 
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potency as dexamethasone.  As one of the most potent non-steroidal glucocorticoids 
reported up to this point this compound showed great potential, however 
disappointingly it has a profile that resembles an inhaled steroidal glucocorticoid drugs, 
with extreme potency high lipophilicity and molecular weight.  A physicochemical 
profile makes it unsuitable for the development of an oral drugs.32 
 
 
Figure 13 
 
1.5   Cortivazol and Non-Steroidal Analogues 
 
As previously highlighted, cortivazol 8 (fig. 5) is a steroidal glucocorticoid, which 
possesses a heterocyclic surrogate for the 3-keto group on steroidal glucocorticoids to 
give rise to a potent glucocorticoid that rivals dexamethasone.22,23 Since its discovery in 
1963, the pyrazole modification has been utilised in a number of studies. 	  
	  
Figure 14 
 
Introduction of the pyrazole into the arylsulfonamide 21 (fig. 14) led to around a 40-
fold increase in GR functional activity with a antagonist profile, which was enhanced by 
the bridgehead benzyl moiety.33 However this compound has no selectivity over PR. 
 
When the neutral pyrazole 23 is replaced by the isosteric and isoelectronic basic 
imidazole 22 (fig. 14) the resulting compound is tolerated by the GR.  However these 
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compounds lack functional activity in transrepression assays, while the analogous 
pyrazole compounds 23 are reported to be partial agonists when secondary alcohols are 
employed.  Tertiary alcohols lead to a significant increase in activity for both the 
pyrazole and imidazole.34-36 Disappointingly, this enhancement leads to an increase in 
transactivation efficacy in the pyrazole examples, while the imidazole examples display 
a dissociated profile with partial agonism in the TR assays and inactivation in TA 
assays.34-36 However direct comparisons cannot be made between the pyrazole and 
imidazole compounds due to differences in the assays used by the three independent 
groups. 
 
1.6   Design of Ligand  
 
Two complementary papers emerged in 2004, which both highlighted the cortivazol 
derivative 24 (fig. 15) as selective and potent non-steroidal GR modulator.35,36 Via a 
survey of the reported glucocorticoids, both groups observed a number of points, which 
contributed to the design of derivative 24. Firstly, the majority of structural 
modifications occur in the C and D rings of the steroid, with the A and B rings only 
experiencing minor modifications such as the addition of fluorine or unsaturation.  Thus 
suggesting that the binding area of the C-D rings is more flexible than that for the A-B 
ring and raising the question whether the C-D rings are required.  Secondly, the 11α 
hydroxyl group on steroidal glucocorticoids has been shown to be important for 
selective binding to the GR over other members of the receptor family.35-37 Lastly, the 
incorporation of heterocyclic A ring appendages, in particular pyrazole, have been 
shown to greatly enhance the anti-inflammatory activity of glucocorticoids.  These 
conclusions led to the investigation of the cortivazol derivative 24, with an aromatic 
moiety acting as a surrogate for the C and D rings.   
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Initially, Shah and Scanlan began their investigations with the arylpyrazole-free 
derivatives 25 (fig. 15), which showed that the ligand binding pocket of GR is tolerant 
for the substitution of C and D rings and by varying the substitution patterns on Ar, 
dissociation between transrepression and transactivation can be achieved.  However 
potencies for these compounds could not be calculated and the fusion of the 
arylpyrazole was considered due to the precedent set by the work by Hirschmann.22  
 
With this adaptation achieved, Scanlan showed that this array of compounds had a GR 
binding in a range of 10-200% of dexamethasone depending on the substitution pattern 
on the aryl ring. Although, they have comparable potencies to the natural 
glucocorticoid, cortisol, they were between 20 to 100-fold less potent than the synthetic 
glucocorticoid, dexamethasone.36 All compounds are selective for the GR over other 
members of the receptor family, while the majority of the compounds tested showed a 
slight dissociated profiles, compounds 26 and 27 (fig. 16) are 10-fold more selective for 
transrepression.36 
 
	  
Figure 16 
 
Ali et al at Merck showed that the small hydrophobic substituents in the ortho and para 
position on the C-D ring surrogate resulted in the best GR ligands, with the 
difluoromethoxy example 28  (fig. 17) producing the optimal dissociation pattern.  It 
was also highlighted that tertiary alcohol derivatives at the 11α displayed a greater 
efficacy and potency than the corresponding secondary alcohols. However this 
improvement was seen in both the transrepression and transactivation assays and did not 
lead to improved dissociated ligands.35  
 
N
N
F
HO
H
26
S
N
N
F
HO
H
27
 
1.   The Glucocorticoid Receptor & Glucocorticoids
 
  14 
 
Figure 17 
 
In addition to the aryl series, the Merck group also investigated replacing the aromatic 
groups with alkyl, alkenyl and benzyl moieties.  Surprisingly the simple alkyl examples 
29 and 30 (fig. 18) displayed significant affinity and functional assay towards GR.  The 
alkenyl series also showed an increase in potency towards GR, with the 4-butenyl 
analogue 31 being the most potent, however this did not result in a dissociated profile.  
Dissociation was achieved with the benzyl series, with the para-methoxy example 32 
being the optimal example observed in this series.  However, these three series did not 
possess the pharmokinetics to allow them to perform well in the in vivo studies.35 
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Another interesting paper relating to this area of research concerning the search for 
selective steroids was by researchers at Johnson and Johnson, who investigated 
adaptations to the progesterone receptor antagonist, mifepristone 5.6 As a member of the 
nuclear steroid hormone family, ligands of the progesterone receptor (PR) suffer from 
the same issues as GR ligands, in particular cross reactivity between the receptors in the 
family and as previously stated mifepristone displays potent GR antagonism.  To 
combat this, substitution of the 7-methylene group for an oxygen gave rise to compound 
33 (fig. 19), which proved to be 10-fold more selective for PR over GR.6 
 
 
Figure 19 
 
These three papers6,35,36 have all highlighted advancements in the search for selective 
steroid receptor ligands. In the search for selective GR modulators, it would be an 
interesting prospect to combine the two findings from these papers to investigate 
whether the substitution of a methylene unit for either an oxygen or heteroatom could 
provide an enhanced selective profile.. In light of this, compound 2 (fig. 20) is the target 
compound for this work.   
 
 
Figure 20 
 
While this work has been primarily focused on the synthesis and application of the 
oxygen analogue 2, hypothetically, it does not need to be restricted to the use of oxygen 
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as the only heteroatom in this position.  The employment of other heteroatoms at this 
position, or any of the alternative positions on this ring, would provide their own unique 
chemical and medicinal profiles.  Nitrogen for example would open up the possibility of 
further variation on its additional bonding position, which may have the potential to 
open up, as yet, undiscovered binding pockets within the GR-LBD.  The possibility of 
installing either sulfur or phosphorus in the same position would bring the similar 
bonding profiles as the oxygen and nitrogen analogues but with ability to increase the 
oxidation levels of the heteroatoms and a significant increase in steric bulk providing an 
added advantage in this instance. 
2.   Synthesis of Wieland-Miescher Ketone Analogue 
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2. Synthesis of Wieland-Miescher Ketone Analogue 
 
2.1   First Synthetic Plan 
 
The route to the carbon analogue 24 has been well documented by both Scanlan36 and 
the Merck group35 from the Wieland-Miescher Ketone (WMK) 34 (scheme 2), which 
after protection of the ketone, involves formylation and reaction with 4-
fluorophenylhydrazine to afford the pyrazole 36.  Deprotection and subsequent 
treatment with potassium hexamethyldisilazide  (KHMDS) and 
(methoxymethyl)triphenylphosphonium chloride will afford aldehyde 37, which will 
yield the target molecule 24 when treated with the appropriate aryl lithium reagent, with 
isomer 24 being reported as the significantly major isomer in most cases or as a single 
diastereomer.35,36  
 
 
Scheme 2: (a) HOCH2CH2OH, pTsOH, 93%; (b) HCO2Et, NaH, C6H6, MeOH, 93%; (c) 4-
fluorophenylhydrazine, NaOAc, HOAc, 41%; (d) 6N HCl, THF, 100%; (e) Ph3PCHOMeCl, KHMDS, 
THF, 75%; (f) PhLi, Et2O, 52-87% 
 
With this precedent, this procedure was viewed as a suitable route for the target 
molecule 2.  Although the synthesis of the Wieland-Miescher Ketone has been widely 
reported in the literature,38-40 the oxygen analogue 1 (fig. 21), required as the starting 
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material for target compound 2, is novel and subsequently, its synthesis would represent 
an important intermediate in this route.   
 
 
Figure 21 
 
A convenient approach would be to follow the pathways that that been previously 
reported and described further in due course for the carbon analogue 34. 2-
methylcyclohexa-1,3-dione 38 (scheme 3) is utilised exclusively as the starting material 
in these synthesises followed by elaboration to the triketone 39, which can undergo a 
Robinson Annulation.   
 
 
Scheme 3 
 
With this synthesis in mind, it would be necessary to synthesise pyran-3,5-dione, which 
has been previously reported.41-44  
 
2.2   The Wieland-Miescher Ketone 
 
The Wieland-Miescher Ketone 34 possesses a simple bicyclic diketone structure, which 
can be accessed via a Robinson Annulation, an aldol derived reaction, which enables the 
formation of three new carbon-carbon bonds to form a 6-membered ring.45,46 Since its 
discovery in 1950, WMK has been widely utilised in the synthesis of a vast number of 
natural products and pharmaceuticals, with the one of the earliest examples being the 
work by Corey et al into the synthesis of longifolene 40 in 1961 and 1964.47,48 
Alongside its elaboration into steroidal structures with adrenosterone 4149 and 
digitoxigenin 4249 below being examples of this, it has also enjoyed an integral role  the 
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synthesis of more complex natural products such as Danishefsky’s synthesis of taxol 43 
in 1996.50  
 
 
Figure 22 
 
The original synthesis of WMK used triketone 39 as the starting material and was 
subjected to sodium hydroxide basic conditions.45 However, in the early 1970s, two 
simultaneous works emerged by Hajos & Parrish51 and Eder et al,39 which utilised the 
simple, commercially available chiral amino acid, L-proline 48, as an asymmetric 
organocatalyst to afford both WMK 34 and its 6,5 bicyclic sister compound, the Hajos-
Parrish Ketone (HPK) 47, from the corresponding triketone in high yields and moderate 
enantiomeric excess. Surprisingly, although this research highlighted the beneficial 
effect of the employment of proline, it was not until the turn of the century that further 
research was conducted into the application of proline and other simple, chiral 
secondary amines as catalysts in organic reactions. Since then a vast number of 
organocatalysts have emerged to catalyse an ever-increasing number of organic 
reactions.52,53 
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Scheme 4: When n = 1 (a) L-proline, DMF, 1M HCl, 7 h, 100 °C, 76%; when n = 2 (a) L-proline, 
CH3CN, 1M HClO4, 25 h, 80 °C, 83%.39 
 
However groundbreaking this initial investigation has been, there are still potential 
issues with this procedure and room for improvements to be made.  Bradshaw and 
Bonjoch report that the Hajos-Parrish proline synthesis affords superior 
enantioselectivity for the HPK 47 over the WMK (93% ee vs. 71% ee).40,54 Alongside 
the use of high boiling point solvents, column chromatography, toxic reagents, which 
all make scaling up the reaction problematic, and the need to undergo numerous 
recrystallisations to afford the pure product, this difference in enantioselectivities has 
meant that further work has been conducted into the synthesis of WMK 34.54  
 
A vast array of catalysts have been reported to promote this reaction to form both HPK 
and WMK, each reporting a variety of yields, enantioselectivities, reaction times and 
catalyst loading.  Some of these new catalysts have built upon the precedent set by 
Hajos and Eder and used proline as the starting point for the design of a new catalyst. A 
selection of this type of catalyst can be seen in figure 23, with the binamprolinamide 49 
being the most successful, affording a 90% ee and 95% yield with a catalyst loading of 
5 mol% after 27 h.55 The prolinethioamide catalyst 50 also afforded a high 
enantioselectivity with 86% ee and 99% yield, again with only a 5 mol% catalyst 
loading over 24 h,56 while the simple prolinamide 51, with the use of pyridinium p-
toluenesulfonate (PPTS) additive resulted in a high enantioselectivity but a moderate 
yield, 87% ee and 68% respectively but required a much higher catalyst loading and 
reaction time at 30 mol% and 144 h.57  
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Figure 23 
 
Other catalysts that have been utilised in the asymmetric organocatalytic formation of 
WMK have structures, which are not derived from the traditional proline.  Although 
interestingly, Davies et al have based their catalyst on an amino acid structure but use a 
β amino acid design rather than the traditional α arrangement to afford the cispentacin 
catalyst 52 (fig. 24).58 This catalyst gave a moderate success yielding 75% of WMK 
with an 86% ee when a catalyst loading of 30 mol% was employed over 108 h but was 
the most successful of a range of β amino acids trialed. The bimorpholine catalyst 53 
was more successful, resulting in a 91% ee and 84% yield with a catalyst loading of 5 
mol% over 70 h.59 A urea based catalyst 54 has also emerged, which affords the desired 
ketone 34 in a high yield, 85% and high enantioselectivity, 95% ee, with a low catalyst 
loading, 10 mol%, and a relatively short reaction time, 16 h.60 This catalyst was 
concurrently employed in the synthesis of the HPK, however this attempt was not as 
successful as for the WMK synthesis, with only a 20% conversion after 94 h but an 
81% ee was achieved.60 
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In addition, a screen of amino acids by Nagamine et al suggested that proline might not 
always be the best amino acid for this type of catalysis.  When investigating the 
synthesis of WMK analogue 60 (scheme 5) from the corresponding triketone 59, the use 
of proline saw a considerable increase in reaction time (132 h) and resulted in a low 
yield and enantioselectivity, 13% and 11% ee respectively, with both the lowest yield 
and % ees in this study.  However the use of both L-leucine 55 and L-methionine 56 
(fig. 24) increased both the yield and enantioselectivity resulting in the highest yield of 
74% and 84% ee. The highest enantioselectivity in this screen was recorded for the use 
of L-phenylalanine 57 as the catalyst at 91% ee and 56% yield.  Notably all the reaction 
times were dramatically reduced from that of proline to 22 h.61 
 
 
Scheme 5: (a) L-amino acid (1 eq), 1M HClO4, DMSO, 90 °C  
 
The researchers also investigated the synthesis of 6,7-bicyclic WMK analogue 62 
(scheme 6) with the same screen of amino acid and again found that L-proline was not 
the best amino acid for this transformation, with only a 7% yield and 6% ee after 114 h.  
The best amino acid in this example was L-methionine 56 which resulted in a 99% yield 
with moderate enantioselectivity, but best for this series, at 53% ee. However a long 
reaction time was still required at 96 h.  Interestingly, when L-arginine 58 was 
employed, the enantioselectivity was reversed to afford the opposite enantiomer 63 in 
an 80% yield with 13% ee.61  
 
 
Scheme 6: (a) L-amino acid (1 eq), HClO4 (0.5 eq), DMSO, 90 °C 
 
This work suggests that L-proline is not the best catalyst to use in the synthesis of 
analogues of WMK, however this is not always the case and a catalyst’s ability to 
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catalyse a Robinson Annulation type reaction depends upon the nature of the analogue 
in question.  Bradshaw et al investigated the synthesis of analogue 65 from its triketone 
precursor 64.  Here 100 mol% of L-proline in DMSO resulted in a 72% yield of the 
desired ketone 65 with 84% ee, after 24 h.  Reduction of the catalyst loading to 25 
mol% increased the reaction time to 48 h and increased the yield to 80 %, however a 
reduction in the enantioselectivity was observed at 74% ee. The optimised conditions 
for this reaction utilised Binam-L-prolinamide catalyst 66 in a solvent free manner, with 
2.5 mol% catalyst loading resulting in a 93% yield and 97% ee.40 
 
 
Scheme 7: (a) catalyst 66 (2.5 mol%), benzoic acid (1 mol%), solvent free, 5 days, rt 
 
Alongside the synthesis of WMK 34, Zhou et al also investigated the synthesis of 
analogues 70-72 with the amine catalyst 73 and WMK was afforded in a 95% yield with 
92% ee. When the methyl group was substituted for a variety of other functionalities, 
the high yields were still maintained ranging from 80-95% but the enantioselectivities 
afforded varied much more greatly, with the benzyl derivative resulting in a 57% ee and 
the alkynyl derivative afforded an enantioselectivity of 92% ee.62  
 
 
Scheme 8: (a) catalyst 73 (10 mol%), mNO2C6H4CO2H (5 mol%), neat, rt 
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2.3   Investigations into the Robinson Annulation 
 
2.3.1   Amino Acid Investigations 
 
Initial investigations into the key Robinson annulation step focused on employing the 
readily available carbon analogue over the more precious and synthetically time 
consuming pyran-3,5-dione 74 (see section 2.4).  Before the key reaction could be 
attempted, synthesis of its precursor was conducted.  
 
 
Figure 25 
 
As with the key Robinson annulation step, there has been much research into the 
synthesis of its precursor 39 and the procedure reported by Gutzwiller et al is one that is 
still being used and built upon today.63 The original procedure involves the Michael 
addition of 2 equivalents of methyl vinyl ketone to 2-methylcyclohexa-1,3-dione 38 in 
the presence of 10 mol% hydroquinone, water and acetic acid63 and has proven to be an 
efficient procedure when used on a large scale.40 However this procedure is less 
successful when it is employed on a small scale and there have been modifications to 
this procedure in recent years. Alterations have been made to the use of base with 
potassium hydroxide64 and catalytic benzyltrimethylammonium hydroxide (Triton B),61 
both in the presence of methanol, providing high yields (93% and 83% respectively) of 
the triketone 39. However it had been triethylamine, which has seen the most prolific 
use as a base in this reaction.58,65-67 One procedure which employs this amine that has 
been widely utilised62,68 since its first report is the one conceived by Bradshaw et al.40 
This solvent free procedure gave the advantage of reducing the traditional large excess 
of the highly toxic methyl vinyl ketone to only 1.1 equivalents and employing a 
catalytic 10 mol% amount of triethylamine to afford the triketone in a 97% yield at 
room temperature.40  
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Scheme 9: (a) Methylvinylketone, NEt3 (1 mol%), 58% 
 
With the evident advantages of this solvent free procedure over the others reported 
(room temperature, short reaction times, low excess of reagents and high yields), it was 
this procedure, which was employed in this work and in the presence of 1 mol%, the 
triketone 39 was furnished in a pleasing 58% yield after 18 h.   
 
 
Figure 26 
 
The preliminary investigation into the cyclisation of the triketone to form WMK 
involved the use of L-proline 48 (fig. 26) as the catalyst. Performed in dimethyl 
sulfoxide (DMSO) with 10 mol% of catalyst at room temperature, the reaction provided 
the WMK in a disappointing yield of 9% after a reaction time of 3 days.  However as 
the literature has shown, organocatalytic ability within amino acids is not limited to 
proline.61 Therefore in addition to the use of proline, investigations were expanded to 
include L-phenylalanine 57 (fig. 26).  However, disappointingly, no product was 
afforded when this amino acid was employed as a catalyst with our system. 
 
 
Scheme 10: (a) 10 mol% L-proline, dimethyl sulfoxide, rt, 3 days, 9% 
 
Although the enantioselectivity of the proline reaction was not investigated, there were 
a number of points where this reaction could be altered to enhance the yield.  However 
O
O
OO
O
a
38 39
N
H
CO2H
48
CO2H
NH2
57
O
O
O O
O
a
39 34
2.   Synthesis of Wieland-Miescher Ketone Analogue 
 
  26 
it was felt that this reaction provided an excellent opportunity to investigate an 
alternative organocatalytic system. 
 
2.3.2   Previous Hydrazine-based Catalysts 
 
An interesting organocatalytic system to emerge recently is that of hydrazines. First 
described by Tomkinson et al, they conceived a catalyst in order to build upon the 
suggestion that efficient and effective catalytic turnover of amine catalysts requires the 
catalyst to possess a highly nucleophilic nitrogen atom, which would accelerate the rate 
determining step; the formation of the iminium ion.69  
 
In order to increase the nucleophilicity displayed by the nitrogen in amine catalysts, 
Tomkinson et al utilised the α effect associated with the introduction of a heteroatom 
bearing a lone pair of electrons, which has the ability to influence the reactivity at the 
adjacent atom, to form the hydrazine moiety in either an acyclic or cyclic fashion.69,70 
Using the Diels-Alder reaction between dienes and electron deficient dienophiles as a 
handle on which to investigate these catalysts, they highlighted the powerful ability of 
the α effect to promote iminium ion catalysis. In particular, the researchers found that in 
addition to an α heteroatom, the introduction of an electron-withdrawing group attached 
to this heteroatom greatly enhances a catalyst’s activity.  
 
 
Scheme 11: (a) 10 mol% catalyst, methanol, rt 
 
Research into this effect initially found that the use of N,O-dimethylhydroxylamine 
hydrochloride 79 (fig. 27) both increased the yield of the reaction between 
cinnamaldehyde 76 and cyclopentadiene 75 (scheme 11) from 7% in the absence of a 
catalyst to 80% and also reversed its selectivity from endo in the absence of a catalyst to 
exo selectivity.  This reversal in selectivity was also noted in the simple secondary 
amine example. However, the catalyst-free selectivity was observed with 
dimethylhydrazine hydrochloride 80 and a reduced yield at 48% compared to the use of 
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hydroxylamine.  Although, this proved to be the exception as upon the introduction of 
electron-withdrawing groups attached to the α heteroatom, the exo-favoured selectivity 
was observed again when the hydrazine amide catalyst 81 (fig. 27) was utilised.  This 
catalyst proved to be the most successful in this study in terms of reaction yield (82%) 
and ease of catalyst synthesis,69 although further work identified the use of the ethyl 
carbamate catalyst 82 (fig. 27) as affording the greatest yield recorded at 98% after a 6 h 
reaction time.70 All ratios of exo: endo products proved to be of a similar value for all 
the catalysts in a roughly 2:1 ratio, although the preference for exo or endo isomers 
depended upon the catalyst employed.69  
 
 
Figure 27 
 
Considering the evidence that cyclic secondary amine catalysts possess enhanced 
activity when compared to their acyclic counterparts, the investigations of Tomkinson et 
al evolved to incorporate this evidence into their catalyst design.71 In contrast with the 
findings with secondary amines, 5-membered hydrazines 83 (fig. 28) produced 
disappointing results even when an electron-withdrawing group was incorporated. 
However, expansion of the ring to six atoms 84 (fig. 28) resulted in an increase in yield 
(99%) when compared to the acyclic examples.  A reduction in the catalyst loading 
from 10 mol% did not lead to an increase in the yield, however halving the reaction 
time from 6 to 3 h did not disastrously affect the yield, affording 90% of the reaction 
product mixture. Again these catalysts yielded a 2:1 ratio of exo: endo products.71  
 
 
Figure 28 
 
In addition to the work conducted by Tomkinson et al, other researchers have used 
hydrazine catalysts to catalyse the Diels-Alder reaction between cinnamaldehyde 76 and 
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cyclopentadiene 75 (scheme 12).  Suzuki et al employed 5 mol% of the urea-based 
hydrazine catalyst 85 (scheme 12), in the presence of 30 mol% p-toluenesulfonic acid 
and DMF, to afford the product in a yield of 91% with a exo: endo ratio of 55:45 and an 
enantioselectivity for the endo isomer of 79 %ee.72  
 
 
Scheme 12: (a) 85 (5 mol%), p-TsOH (30 mol%), DMF 
 
Camphor 86 (fig. 29) and its derivatives, in particular camphor sulfonic acid 87 (fig. 
29), are readily available optically pure compounds and possess great potential as chiral 
catalysts for a range of organic reactions.  The incorporation of hydrazine functionality 
into this naturally occurring terpenoid has led to a number of catalysts, which have been 
employed in the catalysis of the Diels-Alder reaction.  Catalysts 88, 89 and 90 (fig. 29) 
all catalyse the Diels-Alder reaction previously described with a range of medium to 
high yields.73-75 20 mol% of Ogilvie et al’s benzyl derivative catalyst 88 gave the 
highest yield at 96 %, with an exo: endo ratio of 2:1 and providing the endo isomer in 
an 88 %ee.73 Modifying the carbonyl functionality for a sulfonamide in Lee et als’ 
catalyst 89 (fig. 29) did not result in a reduction of the yield (95%), however the exo: 
endo ratio was reduced to 1:1, with the endo isomer being afforded in a 90 %ee.74 
Removal of the alkylation on the hydrazine in Langlois et als’ catalyst 90 (fig. 29) 
resulted in the slight reduction of yield (87%), with the exo: endo ratio affording a 
preference for the exo isomer (1.5:1) but with only a 62%ee.75 However introduction of 
a bromobenzyl moiety 91 (fig. 29) in this position led to an increase in the 
enantioselectivity to 88%ee for both the endo and exo isomers but both the yield and 
endo-exo selectivity were sacrificed at 52% and 1:1 respectively.75  
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Figure 29 
 
In addition to the work that has been described into the use of hydrazine based catalysts 
in the Diels-Alder reaction, researchers have also investigated its use in other organic 
transformation and Jakob et al have employed them in the Michael addition of 
nitroethane 92 to cinnamaldehyde 76.76 Here the hydrazine catalyst 95 produced high 
enantioselectivities of the both the syn and anti products with 82 and 78 %ees 
respectively.  However the catalyst’s effectiveness was significantly reduced with a low 
conversion rate at 4% after a reaction time of 3 days and a 1.1:1 anti: syn ratio.  
Alterations to the catalyst design to afford 96 resulted in an increase in conversion to 
51% over the same reaction time and a selectivity for the anti isomer (1.7:1 anti: syn).  
Although, use of this catalyst did result in the opposite enantiomer being afforded, the 
enantioselectivities were also greatly reduced, with the anti isomer only recording a 5 
%ee.76  
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Scheme 13: (a) 20 mol% catalyst, neat, 50 ºC, 3 days 
 
Building on from Lee et als’ work on the catalysis of the Diels-Alder reaction by 
camphor sulfonyl hydrazine catalyst 89 (fig. 29),74 the same group investigated the 
scope of this catalyst design and have reported its success with the Micheal addition 
reaction between N-benzylindole 96 and crotonaldehyde 97.77 Here 30 mol% of the N-
benzyl analogue 99 produced the product 98 in a 71% yield with an 81 %ee.77  
 
 
Scheme 14: (a) 30 mol% catalyst, 30 mol% trifluoroacetic acid, toluene, - 40 ºC, 20 h 
 
2.3.3   Hydrazine Catalyst Studies into the Robinson Annulation 
 
This work sought to utilise the cheap commercially available hydrazine, dimethyl 
hydrazine dihydrochloride, as the catalyst of choice and investigations began with the 
use of 10 mol% in methanol at room temperature.  After a long reaction time of 3 days, 
pleasingly, a trace amount of WMK was observed.   
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Hydrazines have the potential to behave as both an acidic and a nucleophilic catalyst 
and to enable the advancement of our catalytic system, it was felt necessary to confirm 
the catalyst was acting in a nucleophilic manner.  To rule out the possibility of acid 
catalysis, pyridinium p-toluenesulfonate (PPTS) 101 (scheme 15), which has the same 
pKa as dimethyl hydrazine dihydrochloride 100 of around 5, was employed under the 
same conditions.  Thorough analysis of the reaction material showed no evidence of the 
reaction product confirming that the hydrazine catalyst was acting in a nucleophilic 
manner.   
 
 
Scheme 15: (a) catalyst (10 mol%), methanol, 3 days 
 
With this tentative conformation in hand, attention moved to the effect of the solvent on 
the reaction.  A selection of non-polar and polar solvents were trialed with 10 mol% of 
the catalyst at room temperature for 1 week (table 1). In addition to methanol, both 
dichloromethane (DCM) and dimethylformamide (DMF) showed a trace amount of 
solvent and prompted a further study of chlorinated solvents, alcohols and DMF at 
elevated temperatures.  This resulted in an increase in the yield of WMK when DMF 
was employed to 6%, however the chlorinated solvents DCM and chloroform did not 
result in an increase in yield.   
 
In this study so far, it was methanol that had provided the most optimistic results and it 
was felt further investigation into methanol and other alcohol solvents was necessary.  
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Entry Solvent Temp (ºC) Time (h) Compound Yield (%) 
1 Methanol 20 168 34 6 
2 Dichloromethane 20 168 34 Trace 
3 Toluene 20 168 34 Trace 
4 Dimethyl sulfoxide 20 168 34 Trace 
5 Dimethylformamide 20 168 34 Trace 
6 Tetrahydrofuran 20 168 - 0 
7 Diethyl ether 20 168 - 0 
8 Acetonitrile 20 168 34 Trace 
9 Dichloromethane 40 24 34 Trace 
10 Chloroform 70 24 34 Trace 
11 Dimethylformamide 75 24 34 6 
12 Methanol 65 6 102 80 
13 tert-Butanol 65 3 105 22 
14 Ethanol 65 6 103 42 
15 Isopropanol 65 18 104 96 
16 None 20 168 105 52 
Table 1: Trace compounds determined from crude 1H NMR with characteristic peak at 5.8 ppm 
 
Upon the utilisation of these solvents at 65 ºC, unexpected products were afforded in 
moderate to high yields.  The less hindered alcohols, methanol, ethanol and iso-
propanol yielded the corresponding esters 102-104, while the bridged diketone 
compound 105 was the product when tert-butanol was employed.  Interestingly, the 
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employment of solvent free conditions also resulted in the diketone 105 observed when 
tert-butanol was used. 
 
Interestingly, these compounds have been previously reported as alternative products 
for a traditional Robinson Annulation by Muskopf and Coates.64 When investigating the 
Robinson Annulation, it was found that treatment of triketone 39 with sodium 
methoxide in excess methanol resulted in ester 102 as the major product.  It was 
proposed that these compounds were formed from the cyclic enol 106 (fig. 30) rather 
than the acyclic enol 107, which precedes the Robinson Annulation.  
 
 
Figure 30 
 
Attack of this enol to the acyclic ketone would afford the bridged diketone 105, which 
in favourable conditions could undergo cyclisation by hydroxyl attack of the non-
bridging ketone to yield oxa-twistanol 108 (scheme 16).  Ring cleavage would afford 
bicyclic lactone 109, which could undergo an elimination to yield the carboxylic acid 
110.  With an excess of alcohol present, esterficiation proceeds rapidly to afford the 
corresponding ester.   
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With these undesired products being formed in moderate to high yields in this work, it 
suggests that the nucleophilic hydrazine catalyst is predominately interacting with the 
cyclic ketones rather than the acyclic ketone.  Thus suggesting that the cyclic carbonyls 
are potentially more electrophilic than the acyclic ketone. 
 
At this stage in this work, due to the predominance of these undesired compounds with 
the hydrazine catalyst and the disappointing yields of WMK reported for the other 
solvents and catalysts, investigations into the Robinson annulation on the carbon 
analogue were halted at this point. 
 
2.4   Synthesis of Pyran-3,5-dione 
 
With the carbon analogue of WMK 34, the starting material, cyclohexa-1,3-dione is 
commercially available, which makes its elaboration to the WMK precursor, triketone 
39, a simple, quick and easy synthesis.  However for this work, the oxygen analogue is 
not available commercially and requires synthesis prior to its elaboration to form the 
WMK analogue precursor.   
 
 
Figure 31 
 
One synthetic route towards pyran-3,5-dione 74 was reported in 1977 by Terasawa and 
Okada.43 Their synthesis began with the readily available diglycolic anhydride 111, 
which was subjected to methanolysis and resulted the diester in a near quantitative 
yield.  Treatment with thionyl chloride gave the corresponding acyl chloride 112 
(scheme 17).43 
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Scheme 17: (a) MeOH, HCl (b) SOCl2, 93% (c) R2Cd 
 
The synthetic key alkylation step sought to utilise dialkylcadmium reagents and for 
analogues where the alkyl group being installed was ethyl, propyl and benzyl, the 
reaction was successful in affording the analogues in yields of 50-60%.  However the 
use of both dimethylcadmium and methylmagnesium bromide, which should install the 
methyl (ketone 113 (scheme 17)) needed to yield pyran-3,5-dione 74, did not provide 
the desired compound.  However the employment of methylmagnesium iodide did 
provide ketone 113 in a low yield.  To overcome these disappointing results, Terasawa 
& Okado synthesised ketone 113 via the addition of diazomethane, followed by 
reduction with hydroiodic acid in a 58% yield (scheme 18).  Cyclisation is induced by 
the addition of sodium hydride to afford pyran-3,5-dione in a 47% yield.43  
 
 
Scheme 18: (a) diazomethane, NEt3 (b) HI, 58% (c) NaH, THF, 47% 
 
Despite the use of toxic and explosive materials, this synthesis has been employed by 
Rath et al as the starting material in their model study into the total synthesis of the 
antibiotic Abyssomicin C 117 (fig. 32).78 However, despite its recent use, this procedure 
was not attempted in this work for the above reasons and alternative synthesises were 
sought. 
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Figure 32 
 
An alternative route, which has been reported by a number of groups with variations 
occurring in their choice of reagents, begins with the deprotonation of propargyl alcohol 
118 by sodium hydride followed by the addition of methyl bromoacetate 119 to afford 
the alkyne 120 in a 57% yield (scheme 19).44 Hydration of the alkyne with the 
traditional reagents of mercury acetate and sulfuric acid resulted in a moderate yield of 
the ketoester 113, which was cyclised in a 31% yield with a mixture of potassium tert-
butoxide in tert-butanol.44  
 
 
Scheme 19: (a) NaH, THF, 57% (b) Hg(OAc)2, H2SO4, 55% (c) KOtBu, tBuOH, Et2O, 31% 
 
This synthesis has proved to be a successful one, which has been elaborated by 
Altenback et al in the synthesis of pyran containing dihydropyridines 121 (fig. 33), a 
series of KATP channel openers.42,44  
 
 
Figure 33 
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The use of propargyl alcohol, followed by hydration of the alkyne bond to form a 
pyran-3,5-dione based species was not a novel idea for Altenback et al. It was first 
reported by Morgan and van Heyningen in 1957 and the synthesises both follow an 
identical path, with the choice of ethyl bromoacetate and reagents differing.79 However 
Morgan and van Heyningen did not report the synthesis of the pure pyran-3,5-dione 74 
instead they reported the synthesis of analogues 126 (scheme 20), with variation arising 
from the alkyl groups on the propargyl alcohol. 
 
 
Scheme 20: R = Me, Et, Pr, iPr, C6H13; (a) NaNH2 (b) Hg2+, H+ (c) NaOEt2, EtOH 
 
Lastly, Li et al have designed an alternative route to ketoester 113, which involves the 
use of chloroacetic acid 127 and methallyl alcohol 128 as the starting material (scheme 
21).41 Following esterification, the compound is subjected to a Lemieux-Johnson 
oxidation to afford the ketoester 113, which can undergo a cyclisation in the present of 
sodium tert-butoxide to yield pyran 74 in a yield of 78%.  This synthesis has the 
advantage of being devised for and conducted on a multikilogram scale.  
 
 
Scheme 21: (a) KOtBu, THF, 88% (b) MeOH, Amberlyst, 79% (c) OsO4 polymer bound, NaIO4, THF, 
H2O, 89% (d) NaOtBu, THF, 78% 
 
In this work, both the propargyl alcohol and the chloroacetic acid literature procedures 
were attempted in the synthesis of pyran-3,5-dione 74. Attempts at the propargyl 
HO
EtO
O
Br O OEt
O
O OEt
OO
O
O
O
122 123 124 125 126
a b c
R
R R
R
HO
O
Cl OH HO
O
O MeO
O
O
MeO
O
O
O
O
O
O
127 128 129 130
113 74
a b
c d
2.   Synthesis of Wieland-Miescher Ketone Analogue 
 
  38 
alcohol synthesis resulted in disappointing yields of 37% of the addition product 118 
and 18% of the ketoester hydration product 111.  
 
 
Scheme 22: (a) NaH, THF, 37%; (b) Hg(OAc)2, H2SO4, 18% 
 
Prior to attempts at the cyclisation, synthesis of the ketoester 113 via the chloroacetic 
acid was trialled. The use of the literature procedure conditions resulted in a high yield 
of 70 %, but by altering the conditions to utilise sodium hydride as the base and DMF as 
the solvent, the product 129 was afforded in an increased yield of 94%.  Methylation 
proceeded uneventfully with a yield of 55%, followed by oxidative cleavage to give the 
ketoester in a yield of 42%. 
 
Scheme 23: (a) NaH, DMF, 94%; (b) MeOH, Amberlyst, 55%; (c) OsO4-polymer bound, NaIO4, THF, 
42% 
 
With the ketoester 113 in hand, cyclisation was attempted by both the procedures 
described in the literature.  Crude NMRs suggested that both procedures were 
successful at the cyclisation to afford pyran-3,5-dione.  However issues were 
encountered with the purification of the compound.  
 
Initial purification investigations began with the use of column chromatography, which 
employed 25% methanol and ethyl acetate as the eluent.  This proved to be unsuccessful 
at eluting the product from the column.  Further investigations turned towards the 
literature procedures, which have not employed chromatography as a route towards 
purification and instead have utilised recrystallisation techniques exclusively.  However, 
there is not a concenus on the perfect solvent mixture to achieve a successful 
recrystallisation amongst researchers, with Alternbach et al 44 employing a 1:1 
combination of hexanes and ethyl acetate, while Li et al41 utlised solely ethyl acetate.  
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Within this work, both of these combinations were trialled but to no avail on both 
counts.   
 
2.5   Summary of Robinson Annulation Approach 
 
With the difficulties encountered with the isolation of pyran-3,5-dione and also the 
disappointing results of the  Robinson annulation investigations, concerns were raised 
regarding the viability of this approach.  The investigations into the Robinson 
annulation resulted in a low yield of the desired WMK and the prevalence of the esters 
102-104 (fig.34) as the reaction product when a hydrazine catalyst was used.  
 
 
Figure 34 
 
With the latter’s formation being due to deprotonation of the cyclic ketone, giving rise 
to 106 (scheme 24) rather than the expected deprotonation of the alkyl ketone, 107, 
being the greatest cause of concen.   Thereby suggesting that the electronegativity of the 
cyclic ketones is slightly greater than the acyclic ketone.  It was felt that the 
introduction of the oxygen into the cyclohexane in the β position would increase this 
electronegativity, thereby giving rising to the enolate 132 and potentially yielding the 
unwanted ester 133.  However the inability to synthesis and isolate the pyran 74 did not 
allow for the testing of this hypothesis. 
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Scheme 24 
 
2.6   New Approach to Wieland – Miescher Ketone Analogue 
 
2.6.1   Retrosynthetic Analysis 
 
At this point it was thought necessary to reconsider the approach to the synthesis of the 
WMK analogue 1.  With the literature only describing Robinson Annulation synthesises 
towards WMK 34, this new thought process represents a novel approach.   
 
As the Robinson Annulation approach utilises the use of the pyran as a template for 
further elaboration, it was thought beneficial to avoid this and use the carbocycle as the 
core, with the pyran built around it.  The obvious first disconnection, with this in mind, 
is to disconnect along the carbonyl and carbocycle bond, leaving a negatively charged 
carbon on the carbocycle.  Tautomerisation can afford the enolate 135 (scheme 25), 
which, with the conjugated diene in the carbocycle, looks close to aromaticity, thereby 
suggesting a key step of a Birch reduction. 
 
 
Scheme 25 
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Further disconnections involved the removal of the methyl and the acetic moiety to 
afford inexpensive and commercially available 3-hydroxybenzyl alcohol 138 (scheme 
26).   
 
 
Scheme 26 
 
Two potential synthesises were foreseen from this starting material encompassing a key 
Birch reduction step.  The first sees the Birch reduction as the first step, with the 
hydroxyl controlling the regioselectivity of the reduction. Addition of chloroacetyl 
chloride to the benzyl alcohol would afford acyl chloride 140 (scheme 27), which could 
be cyclised and the methyl added at the end of the synthesis.  
 
 
Scheme 27 
 
In our projected synthesis, the free phenol hydroxy in 139 has the potential to interfere 
with the forward synthesis. Particularly, during the addition of chloroactyl chloride to 
afford 140, where it is envisioned would employ the reagent mixture of sodium hydride 
and DMF.  In this step, selectivity of the addition would be questionable, with 
potentially a mixture of addition on to the primary alcohol or the enol being afforded.  
In view of this, it would be pertinent to protect the hydroxyl as a methoxy, which would 
maintain the desired regioselectivity of the Birch reduction and be stable enough to 
survive the basic nature of the majority of steps.  Conveniently, the 3-
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methoxybenzylalcohol 142 (scheme 28) is commercially available, thereby removing 
the need to conduct the protection and the danger of double methylation.  
 
 
Scheme 28 
 
Additionally, this starting material and synthesis, advantageously has the potential to 
give increased control of the Birch Reduction’s regioselectivity.  However, there could 
be disadvantages with this route as a base induced methylation could see methylation in 
the 2 position adjacent to the pyran oxygen seen in 143 (fig. 35), rather than the desired 
methylation at the more hindered 4 position as in 144. 
 
 
Figure 35 
 
The second projected synthesis (scheme 29) would also utilise 3-methoxybenzyl alcohol 
142 as the starting material and the pyran would be formed prior to the Birch reduction.  
There would be issues around the reduction, however, as the methoxy and keto moieties 
would be in competition over control of the reactions regioselectivity (see section 2.6.2 
for more details). This step could be followed by methylation, which would also install 
the alkene in the correct position for WMK, to afford compound 144 and deprotection 
of the methoxy would afford the WMK analogue.  
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Scheme 29: (a) chloroacetic acid, NaH, DMF (b) thionyl chloride, Lewis Acid (c) Na, NH3(l) (d) LDA, 
MeI (e) HCl 
 
It has come to our attention that a similar route has previously been undertaken to 
synthesis another WMK analogue 150.80 However, while the product is different in this 
work and the researcher begin their synthetic route further along the synthesis than 
suggested here, this work provides confidence in the potential success of this new 
approach.   
 
 
Scheme 30: (a) Na(s), EtOH, NH3(l), Et2O (b) Al(OiPr)3, Acetone, toluene, 100% (c) KNH2, NH3(l), Et2O, 
MeI, 100% (d) Oxalic acid dihydrate, acetone, 90%. 
 
2.6.2   The Birch Reduction 
 
 
Scheme 31: (a) Group 1 metal, NH3(l) 
 
The Birch reduction, otherwise known as a dissolving metal reduction, is a powerful 
synthetic tool, which enables the reduction of an aromatic ring to an unconjugated 
cyclohexadiene 149 (scheme 31), in the presence of a group 1 metal and liquid 
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ammonia.81,82 Its utility has been demonstrated in a number of total synthesises as 
shown in figure 32.83-87  
 
 
Figure 36 
 
First reported in 1937 by Wooster and Godfrey,88 the scope of the reaction was fully 
investigated by Birch in the 1950s89,90 and it employs the electron that is released when 
group 1 metals, sodium, lithium or potassium, dissolve in liquid ammonia.  This 
solvated electron gives the characteristic blue colour associated with the Birch 
Reduction reaction mixture and will reduce ammonia to amide and hydrogen gas.  As 
this transformation is slow, an aryl ring 151, which is a better electron acceptor than 
ammonia, will preferentially be reduced, with the electron filling the antibonding 
LUMO, forming a radical anion 153.82,91 The anion will readily accept a proton from a 
proton source, usually ethanol or tert-butanol, leaving a radical species 154, which will 
form an anion upon reaction with another solvated electron.  Again exposure to a proton 
source will quench the anionic charge yielding the 1,4-diene product 152.82,91  
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Scheme 31 
 
During the process of the reduction the anions and radicals are delocalised within the 
ring, thereby allowing the option of a conjugated diene or an unconjugated diene.  The 
Birch reduction exclusively yields the unconjugated isomer.  
 
The regioselectivity of this reaction is not only limited to the nature of conjugation of 
the dienes but their position, in relation to substituents on the ring, is influenced too by 
the nature of these substituents.  The key mechanistic step in the Birch reduction is the 
protonation of the radical anion intermediate 153 (scheme 31), which is formed after the 
initial electron transfer and this determines the regioselectivity of the product. An 
electron donating substituent 158 (scheme 32) will result in a decrease in reaction rate 
with protonation favoured at the ortho position, resulting in the substituent in a non-
reduced position in the product 159.82,91,92 On the other hand, an electron withdrawing 
substituent 156 will see an increase in the rate of the reaction and favour protonation at 
the para position, resulting in the substituent in a reduced position on the ring 
157.82,91,92  
 
 
Scheme 32 
 
2.6.3   Investigations into Birch Reduction followed by Cyclisation Synthesis 
 
Surprisingly, the Birch reduction of 3-methoxybenzylalcohol 142 has not been 
documented in the literature.  However its analogue, 4-methoxybenzylalcohol 160, 
has93-95 and all these procedures utilise sodium metal and tert-butanol alongside liquid 
ammonia.  With this combination of reagents being successful for its analogue, they 
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were employed in the attempted reduction of the meta analogue 142.  However the 
initial investigation was unsuccessful, yielding only starting material.  As the 
characteristic blue colour of solvated electrons seen in Birch reductions was not 
observed in this first reaction, the sequence of additions for reagents was reversed with 
the metal being added prior to the benzylalcohol to ensure that the electrons responsible 
for the reduction were present. Again this failed to produce the desired product, yielding 
only the starting material 142.   
 
 
Scheme 33: (a) Na(s) (4 eq), EtOH (35 eq), NH3(l) 
 
In light of the inability to afford the complete reduction of 3-methoxybenzyl alcohol 
142, investigations into this synthetic route was not furthered in this work. 
 
2.6.4   Investigations into Cyclisation followed by Birch Reduction Synthesis 
 
With the first key intermediate in this synthetic route being the cyclised aromatic ketone 
145, it was important to identify the most efficient synthesis towards it.  Acylation of an 
aromatic ring can be achieved through a number of routes, Friedel – Crafts Acylation, 
Vilsmeier – Haack reaction and the Houben-Hoesch Reaction.  
 
2.6.4.1   Friedel-Crafts Acylation Investigations 
 
This classic reaction, which has been widely utilised in both an inter- and 
intramolecular fashion,92 employs either an acyl chloride or an acid anhydride in the 
presence of a Lewis acid to produce either a fully dissociated acylium ion 164 or a 
complex of both the Lewis acid and acyl chloride 165, depending upon the electronic 
makeup of the aryl ring.91,92 In light of the mechanistic work conducted by Sato et 
al,92,96 which showed that the acylium ion 164 is kinetically dominant when the aryl 
ring is either electronically evenly balanced (benzene) or contains EWG, the Friedel-
Crafts acylation needed in this work would mechanistically depend upon the complex 
165. 
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Scheme 34: (a) AlCl3 
 
In the literature, ketone 146 has been previously synthesised via a Friedel-Crafts 
acylation of the acid 167.97,98 Both groups employed tin(IV) chloride as the Lewis acid 
in the transformation and with a yield of 52% reported, this procedure provided a 
logical starting point for these investigations.  Synthesis of the acid was reported by 
Ramadas et al and utilised a 2-step route via the addition of ethyl bromoacetate to 3-
methoxybenzyl alcohol to afford ester 166, followed by hydrolysis to yield the acid 167.  
 
 
Scheme 35: (a) Na(s), benzene; (b) ethyl bromoacetate, benzene, 40% (over two steps); (c) 10% KOH in 
methanol, 68% 
 
A number of disadvantages were highlighted with the employment of this procedure 
into our synthesis.  Firstly, an additional two-steps were added to the synthesis and 
utilise a number of hazardous reagents.  In addition to its useable but underwhelming 
yields, it was felt that investigations should be conducted into the viability of 
conducting this transformation in a single step, in line with our previous work into the 
addition of chloroacetic acid 127 and methallyl alcohol 128 (scheme 36). 
 
 
Scheme 36: (a) NaH, DMF, 94% 
 
With this previous work in mind, sodium hydride and DMF were successfully utilised 
to perform this one step transformation providing the acid 167 in a 96% yield.  This 
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fully optimised reaction protocol employs 4 equivalents of the base in a concentrated 
solution of 3.4 M.  The concentration of the reaction mixture did prove to be an 
important feature of this reaction with the reaction proceeding more successfully in the 
more concentrated examples (table 2). 
 
 
Concentration (M) NaH (Eq) Yield (%) 
0.2 3 61 
0.1 6 46 
0.7 6 67 
0.7 5 54 
1.1 5 60 
2.5 4 80 
3.4 4 96 
Table 2: (a) chloroacetic acid (1 eq.), 3-methoxybenzyl alcohol (1.2 eq), NaH, DMF, 80 ºC, 20 h. All 
reactions employed an acid-base extraction as the method of purification. 
 
As a point of interest, THF was trialed producing a complex mixture of products, which 
proved onerous to purify and yielded only 17% of the desired acid 167. In addition, 
changes in the purification method provided notable increases to the product yield, with 
an acid-base extraction proving an improved method over column chromatography.   
 
As previously noted both Ramadas et al and Runyon et al afforded the cyclised ketone 
145 from the corresponding acyl chloride 168 with the Lewis acid reagent being tin(IV) 
chloride.97,98 However, differences arise from their use of chlorinating agent with 
Runyon et al employing oxalyl chloride and Ramadas et al utilising thionyl chloride but 
this difference does not affect the yield of cyclised product 145 as both groups report 
yields of around 50%.   
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Scheme 37: (a) (COCl)2 or SOCl2 (b) SnCl4, 50% from two steps 
 
In this work, oxalyl chloride was chosen in the first instance to act as the chlorinating 
agent alongside a catalytic amount of DMF, while the cyclisation step was investigated.  
With both papers using tin(IV) chloride in either excess or equimolar amounts, initial 
investigations employed one equivalent of tin(IV) chloride to successfully afford 42% 
of the cyclised ketone 145. Increasing the reaction time from the reported 1 h to 3 h, 
increased the yield by a fraction to 47%.  However given the toxicity of tin compounds, 
it would be advantageous for the potential scale up of the reaction to reduce the amount 
of SnCl4 employed in this step and the initial reduction to 50 mol% of SnCl4 yielded a 
positive 50% of cyclised ketone 145.  However, further reduction to 25 mol% resulted 
in an increased reaction time to 5 h and a reduction in the yield to 22%.  The ideal 
amount of SnCl4 needed for the cyclisation was found to be 40 mol% resulting in a 
maximum of 66% of cyclised ketone 145. The less successful use of thionyl chloride as 
the chlorinating agent is highlighted in entry 6 of table 3, with a reduction in the yield to 
39%. 
 
Entry SnCl4 (mol%) Time (h) Yield (%) 
1 100 1 42 
2 100 3 47 
3 50 3 50 
4 25 5 22 
5 40 3 66 
6a 40 3 39 
Table 3: All reaction take place using acid chloride made in situ with an excess of (COCl)2 and are 
conducted at 0 ºC. (a) Acyl chloride made with an excess of SOCl2. 
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Although the major product from these reactions is the cyclised ketone isomer 159, the 
alternative isomer 169 is also recovered as a minor product in a 5% yield.   
 
 
Figure 37 
 
Although SnCl4 displayed significant competence at the successful cyclisation of acid 
chloride 168 (scheme 37), concerns were still raised regarding the hazardous nature of 
this compound and the search for an alternative Lewis acid was conducted.  This trial 
employed aluminium trichloride, boron trifluoride diethyl etherate, zinc(II) triflate and 
samarium(III) triflate.  Disappointingly, none of these Lewis acids resulted in the 
desired product, yielding only starting material.  This raised the idea that the cyclisation 
could be Brønsted acid catalysed rather than Lewis acid catalysed and that SnCl4, which 
is used as a commercially available 1M solution in DCM, is providing an anhydrous 
source of hydrochloric acid.  However the use of strong acids, methanesulfonic acid and 
triflic acid, did not yield the desired product, leading to the continued use of the 
previously optimised SnCl4 conditions. 
 
2.6.4.2   Vilsmeier-Haack Reaction Investigations 
 
The Vilsmeier-Haack reaction is an aromatic acylation reaction, which employs a 
substituted amide in the presence of phosphoryl chloride (POCl3) to form a 
chloroiminium ion, also known as the Vilsmeier reagent, which can act as an 
electrophile despite the absence of a Lewis acid.92 First reported in 1927, this reaction 
has enjoyed wide spread use in the synthesis of heterocycles99-106 and within natural 
product synthesis.107-110  
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Figure 38 
 
In this work, it was decided to employ this technique in a relatively underused 
intramolecular manner.  In comparison to the intermolecular sister reactions, the 
intramolecular Vilsmeier-Haack reaction features sparsely in the literature.  Meth-Cohn 
and colleagues have described the use of an intramolecular Vilsmeier-Haack reaction to 
furnish a quinoline 171 from the acylanilide 170. Here, the Vilsmeier conditions are 
utilised to perform, firstly, the formylation of the amide to yield the α-chloroenamine 
followed by the acylation to give quinoline 171.111 
 
 
Scheme 38: (a) POCl3, DMF, 120 ˚C 
 
To attempt this type of reaction in this work, installation of the amide functionality was 
required.  With amidations between an amine and a carboxylic acid requiring high 
temperatures to facilitate the necessary elimination of water to yield the product, it was 
felt that direct amidation of the acid 167 might prove to be detrimental.112,113 As such 
synthesis of the amide prior to reaction with alcohol 142 was approach taken.  In order 
to afford a higher yield of amide 173, the available acid chloride 172 was employed in 
place of the corresponding chloroacetic acid 127, which would allow for the correct 
functionality to allow for appendage to the benzylalcohol 142, as well as enabling a 
higher yielding and speedier reaction time.113  
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Scheme 39: (a) HNMe2, THF, 50%; (b) 3-methoxybenzyl alcohol 139, NaH, DMF, 79%. 
 
Upon production of amide 173, the reaction with benzylalcohol 142 was performed in 
the same manner as previous reactions with sodium hydride and DMF, yielding the 
amide 174 in a 79% yield.   
 
Attempts at the intramolecular Vilsmeier began with the use of an excess of POCl3, 
initially at room temperature followed by heating to 50 °C and then 80 °C.  
Unfortunately, these conditions did not result in the desired product.  Both thionyl 
chloride and oxalyl chloride were trialed as alternative chlorinating agents.  Although 
both have been utilised as Vilsmeier reagents,92,114,115 they were again unsuccessful at 
furnishing ketone 145 from amide 174.   
 
 
Scheme 40: (a) Tf2O, 17% 
 
Although traditional Vilsmeier reagents have not produced the desired products in this 
work, there is scope within the literature for Vilsmeier-type reaction to occur with 
unorthodox reagents.  The one that proved to be successful in this work was first 
reported by Black in the 1990s,116,117 employing triflic anhydride, which has been 
shown to be versatile in other Vilsmeier-Haack type reactions.118-120 When our amide 
174 was subjected to this reagent, it did prove successful in affording the acyl ketone 
145. However the long-term employment of this synthetic method was put into doubt 
due to the low yield obtained at 17%.  
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2.6.4.3   Houben-Hoesch Reaction Investigations 
 
The Houben-Hoesch reaction is a method of affording aromatic ketones from the 
aromatic electronic substitution of nitriles.121 First described by Hoesch in 1915122 and 
Houben in 1926,123 this reaction has not enjoyed the recognition that the Friedel-Crafts 
and Vilsmeier-Haack reactions have.  However despite its low key presence within the 
literature, it has been employed in the synthesis of a number of natural products124-126 
and examples of intramolecular transformations are also present.127,128  
 
 
Figure 39 
 
Installation of a ketone functionality through an imine intermediate is initiated by the 
protonation of the nitrile, traditionally by the use of a Lewis acid-Brønsted acid 
mixture.96 However, the use of strong organic acids have proved to be more reliable 
reagents for the transformation, with triflic acid and trifluoroacetic acid being readily 
employed.96,127,128 
 
 
Scheme 41 
 
In this work, the nitrile functionality was installed by utilising 3-methoxybenzyl alcohol 
142 and bromoacetonitrile 178 under the same sodium hydride/DMF conditions used 
previously to give nitrile 179 in a disappointing 17% yield.  
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Scheme 42: (a) NaH, DMF, 17%  
 
Exposure of this nitrile 179 to Houben-Hoesch superacid conditions began with the use 
of excess methanesulfonic acid, which, disappointingly, resulted in a reaction product, 
which was unable to be isolated and identified.  Reduction of the amount of acid to a 
catalytic 50 mol% amount again resulted in the same black, unidentifiable reaction 
mixture.  Increasing the acidity of the reaction mixture with the use of triflic acid again 
gave no identifiable product, while reducing the acidity by employing concentrated 
sulfuric acid resulted in yielding the starting material.    
 
 
Entry Acid Equivalents Solvent 
1 CH3SO3H excess None 
2 CH3SO3H 0.5 DCE 
3 CF3SO3H 1.2 DCE 
4 H2SO4 1.2 DCE 
5 (CF3SO2)2O 1.5 DCE 
Table 4 
 
With no desired reaction product or alternative products being formed from this route, 
further elaboration and investigation were not undertaken. 
 
2.6.5    Birch Reduction of 7-Methoxyisochroman-4-one 
 
With the most synthetically viable route to 7-methoxyisochroman-4-one 145 being via a 
Friedel-Crafts acylation, the Birch reduction could be attempted.  Although, the 
reduction of aryl ketone 145 has not been reported within the literature, the carbon 
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analogue 180 (scheme 43)129 has, alongside the work by Ireland et al into the seven 
membered analogue.80 As it can seen from the Paquette et al synthesis in scheme 43 and 
the Ireland et al synthesis in scheme 28 (section 2.6.1), both groups of researchers 
successfully employed sodium and liquid ammonia to afford the Birch reduction, which 
incidentally also reduced the ketone in both cases.  Oxidation has been achieved with 
both examples by the use of an unusual oxidising agent, aluminium isopropoxide, and 
the subsequent alkylation is achieved with the employment of potassium amide as the 
base and an appropriate alkyl halide. 
 
 
Scheme 43: (a) Na(s), NH3(l), 67% (b) Al(OiPr)3, acetone, toluene, 88% (c) KNH2, RCl, NH3(l), (not 
isolated) 
 
The precedence of this work in the literature gives confidence that the Birch reduction 
of our aromatic ketone 145 will proceed with the desired regioselectivity for the forward 
synthesis.  Alongside the methoxy-directed reduction, these examples also suggest that 
the reduction of the ketone should also be expected, with diene 183 being the predicted 
outcome for our reaction.  When treated with 7.5 equivalents of sodium metal in liquid 
ammonia and excess ethanol, the reduction proceeds as predicted yielding diene 183 in 
a 58% yield.   
 
 
Scheme 44: (a) 7.5 Na(s), NH3(l), EtOH, Et2O, 58% 
 
Although this reaction did prove to be successful in the synthesis of diene 183, it was 
also a rather unreliable and capricious reaction.  Several changes to the reaction 
conditions were made to try to overcome this.  Changing the metal from sodium to 
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lithium did not provide the product, while changing the co-solvent from anhydrous 
ether to anhydrous THF also resulted in a slight drop in yield to 45%. 
 
Despite, the unpredictability of this reaction, enough material was afforded to take 
through to the next step.  The oxidation has previously been achieved with the 
analogous 6-membered 184129 and 7-membered 18580 carbocycles with the use of the 
Oppenauer Oxidation, which employs a metal alkoxide acting as a Lewis acid, 
alongside a simple ketone, usually acetone or butanone.82,130 Usually performed in 
toluene or benzene, this simple, easily accessible reagent mixture has the advantage of 
being highly selective for the oxidation of secondary alcohols to ketones with no over 
oxidation observed or interference with other functionality within the molecule.82,130-132  
 
 
Figure 40 
 
Both Paquette129 and Ireland80 used catalytic aluminium isopropoxide and acetone 
mixture in toluene.  With this being successful in their examples, it was applied to the 
alcohol analogue 184 in this work. This was equally successful yielding ketone 146 in a 
58% yield with no rearomatisation of the reduced ring observed.  This observation is 
noteworthy as, in addition to the employment of the Oppenauer oxidation, an alternative 
oxidant was trialed.  Use of the widely utilised Dess-Martin Periodinane (DMP) was 
successful at the oxidation of the alcohol to ketone, but it also resulted in providing a 
significant amount of rearomatised product 145.   
 
 
Scheme 45: (a) Al(OiPr)3, acetone, toluene, reflux, 58% 
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At room temperature, the use of 150 mol% of DMP in the presence of lutidine resulted 
in 1:1.6 mixture of ketone 146 and aromatic product 145.  Cooling of the reaction 
mixture to –10 °C leads to a reduction in the amount of aromatic product recovered with 
the ratio between 146:145 being 1:0.5.  Unfortunately, further reaction cooling did not 
result in further reduction of amount of aromatic product afforded.   
  
The next step in the synthesis was the methylation of the hindered 4 position adjacent to 
the newly formed ketone. To provide the required regiochemistry necessary for the 
product, deprotonation at the 8 position as shown in structure 185 and subsequent 
tautomerisation 186, was required to facilitate this.  
 
 
Scheme 46 
 
Previous literature synthesises80,129 have utilised amide bases to achieve this enolate 
formation, with methyl iodide acting as the methylating agent.  The base of choice has 
been potassium amide, which is made in situ from potassium metal and liquid ammonia.  
Wishing to avoid the use of both these hazardous materials in this work, an alternative 
base was sought and initial investigations continued to concentrate on amide bases but 
began with lithium diisopropylamine (LDA).  Being a base that is routinely used in 
enolate formation,82,91,133,134 we were confident that the methylated product 144 would 
be rapidly yielded.  At a range of temperatures from −78 °C to room temperature, the 
methylated product was not observed and instead an inseparable product mixture was 
isolated.   
 
Although amide bases have been the base of choice by previous researchers, they have 
limited themselves to the use of those where potassium is the counterion with Paquette 
et al129 and Ireland et al80 using potassium amide, while Ireland & Thompson135 and 
Smith & Richmond136 employed potassium hexamethyldisilazide (KHMDS). Both the 
two latter research groups did trial and report the use of lithium amide equivalent bases 
but to no avail with recovered starting material being afforded. Although in the case of 
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Smith & Richmond, LDA had proved effective at producing the desired deprotonation 
and rearrangement in an earlier model study.  The major difference between the model 
and their actual system was the level of oxygenation within the molecule, with the 
model system bearing significantly less oxygen atoms than the actual one.  This 
observation ties in with the hypothesis made by Ireland135 that the hard nature of the 
lithium counterion interacts strongly with the oxygen atoms within the molecule thereby 
preventing the base’s further approach to the desired site of deprotonation.  With 
thought given to the observations made thus far to our system, it could be argued that 
the lithium counterion of LDA is strongly coordinating to the cyclic oxygen of the B 
ring (structure 187 (Fig. 41)) rather than the methoxy oxygen (188) and also potentially 
to the ketone, thereby removing the base from the site of deprotonation on carbon 8. 
 
 
Figure 41 
 
As potassium bases have proved successful for this transformation in the literature, 
further investigations on our system concentrated on the use of KHMDS and following 
the initial investigation with 2 equivalents of base, a trace of the methylated compound 
144 (scheme 47) was yielded.  However repetition of the reaction conditions and 
alterations to these conditions did not lead to the completion of the reaction and instead 
yielded a mixture of starting material 146, methylated 144 and rearomatised product 
145.  
 
 
Scheme 47: (a) KHMDS (1 eq.), MeI, THF, 23% 
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With as much as 60% starting material being recovered, patterns emerged from the 
trialing of a number of conditions, firstly, an increase in the equivalents of base to 5, led 
to a decrease in the yield of methylated product 144 to zero, while the reduction of the 
amount of base to equimolar gave the greatest yield of methylation at 23%.  In addition, 
this reduction of base also reduced the ratio between methylation and rearomatisation 
with only a trace of ketone 145 afforded in this example.   
 
 
 
Entry 
 
Base 
 
Equivalents 
Yield (%) Yield (%) 
1 KHMDS 2 Trace 0 
2 KHMDS 5 0 6 
3 KHMDS 1 23 Trace 
4a KHMDS 1 6 5 
5b KHMDS 1 12 5 
6c KHMDS 1 6 3 
7 LiHMDS 1 0 0 
8 LiHMDS 5 0 0 
Table 5: (a) Solvent degassed prior to addition of reactants and reagents; (b) TEMPO used as an additive; 
(c) addition of MeI prior to addition of base 
 
Secondly, with the thinking that the rearomatisation was due to the presence of oxygen 
within the solvent (THF), a number of examples underwent degassing to investigate this 
hypothesis.  However as it can be seen from entry 4 in table 5, this did not prove to be 
successful in increasing the yield of the methylated product 144.  Secondly, the addition 
of the radical inhibitor, TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxyl did increase the 
ratio of methylation 144 over rearomatisation 145, thereby suggesting that the 
rearomatisation occurs via a radical mechanism (entry 5 (table 5)).  
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The suggested radical mechanism for the rearomatisation is shown below in scheme 48, 
which shows the radical addition of oxygen at the hindered 4 position 193.  This 
presents the compound with a perfectly situated leaving group, which given the 
presence of KHMDS as a base, readily undergoes an E1CB mechanism to afford the 
product. As detailed further in section 3.1, recent and ongoing work within the Wilden 
group has focused upon the fast radical reaction of potassium alkoxide salts.137 Building 
on from these initial studies, the group also has evidence that potassium enolates behave 
in a similar radical manner,138 which supports and gives confidence in our suggested 
mechanism (scheme 48) for this side product. Although direct mechanistic studies have 
not been undertaken on this example. 
 
 
Scheme 48 
 
Thirdly, the majority of the reaction conditions saw the addition of base to the diene 146 
prior to the addition of the methylating agent, with the view to ensure complete to 
protonation.  However, TLC evidence of this initial reaction mixture showed the 
presence of the aromatic ketone 145. In order to attempt to prevent the formation of this 
ketone 145, methyl iodide was added to the reaction mixture prior to the base, with the 
view that once the enolate was formed it could be trapped by the methylating agent 
hopefully before rearomatisation could occur.  However entry 6 shows that this again 
was not successful.   
 
All the examples described above utilise the base KHMDS and in order to confirm the 
inability of the lithium counterion to afford the required product, LiHMDS was also 
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trialed under the equimolar and excess conditions.  Again, both these examples did not 
yield either the methylated product 144 or the aromatic ketone 145.   
 
2.7   Conclusion and Further Work 
 
This work has documented two attempted synthesises in the development of the 
Wieland-Miescher Ketone analogue 1, as a key intermediate in the synthesis of potential 
glucocorticoid receptor modulators 2. Although the synthesis of modulators 2 was not 
able to be attempted, this work has been successful at producing the methoxy-protected 
Wieland-Miescher Ketone analogue 144; however more research is required to provide 
144 in a reliable and high yielding manner. 
 
 
Figure 42 
 
During the course of the initial unsuccessful route towards 1, our investigations into the 
development of a novel organocatalysts for the Robinson Annulation of carbocycle 34 
resulted in some relatively obscure products.  The use of the traditional proline catalyst 
for the formation of WMK produced a low yield of WMK, while employment of 
catalytic commercially available hydrazine in the presence of an alcoholic solvent 
resulted in the unexpected formation of esters 102-104 in high yields.   
 
It was from the high yields of these esters that we drew the conclusion that, with regards 
to the carbon analogue 34, the nucleophilic and acidic nature of the cyclic keto α 
protons were greater than that of the acyclic equivalents.  Therefore, the introduction of 
an electronegative oxygen within the carbocycle would result in an increase in the 
nucleophilic and acidic nature of the neighbouring protons. Thereby, increasing the 
difference between the cyclic and acyclic keto α protons and resulting in enolate 
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formation exclusively within the pyran and formation of the β ethyl esters 139. Thus 
making this an unviable route towards the desired WMK analogue 1. 
 
 
Scheme 49 
 
Our second route has proved to be a more successful and in comparison displays a more 
synthetically interesting synthesis.  With use of the Birch reduction as a key step, this 
route involves five steps to yield the penultimate methoxy analogue 144 in a mixture of 
moderate to high yields. To complete the synthesis, a further deprotection step is 
required to yield the desired WMK analogue 1.    
 
 
Scheme 50: (a) NaH, DMF, 80%; (b) Oxalyl chloride, SnCl4, DCM 50%; (c) Na(s), NH3(l), EtOH 40%; (d) 
Aluminium Isopropoxide, toluene, acetone 58% 
 
However this route is far from perfect and can be improved upon in a number of ways. 
Firstly, as noted previously, the key Birch reduction step does suffer from being 
capricious and attempts to improve its reliability through changes to the metal to 
lithium, thus far have failed.  One interesting development with in the realm of Birch 
reductions that should be investigated, is that of ammonia-free Birch reductions.  
Donohoe has pioneered this new approach, which provides synthetic advantages with 
regards to the practicability of the reaction conditions.139 The use of lithium di-tert-
butylbiphenyl (LiDBB) 194 as an electron carrier in place of liquid ammonia, seen in 
the traditional Birch, has been demonstrated in the total synthesis of the protease 
inhibitor, clasto-lactacystin β-lactone.140,141  
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Figure 43 
 
Secondly, the methylation step, currently suffering from both low yields and a 
capricious nature, requires improvement.  Initial improvements could be trialed through 
the employment of a simpler amide base.   To date, the amide base that has been 
employed is KHMDS, while Paquette et al129 used the simple potassium amide 195 to 
deprotonate and alkylate at the same position.  Although this base requires in situ 
preparation via the employment of liquid ammonia and potassium metal, it should be 
the first point of investigations for improvements. Another potassium base, which at 
first glance would seem a logical progression given the prolific nature of its lithium 
counterpart for this type of reaction, is that of potassium diisopropylamide 196 (KDA).  
However, unlike LDA, the preparation of KDA is not a trivial endeavour with a reliable 
general method currently proving elusive.142-144  
 
 
Figure 44 
 
Further efforts could be sought through the use of a less hindered methylating agent.  
Methyl iodide is a highly successful methylating agent, however it does have the 
disadvantage of being rather bulky which in terms of this reaction could be highly 
significant.  The use of both chloromethane and bromomethane could be a option, 
although thought would need to be given to the safe handling of both products given the 
toxic and gaseous nature of both compounds.  However, alternative agents could be 
sought from the employment of methyl methanesulfonate, which although bulky could 
be beneficial as a softer electrophile.   
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3.   Investigations into the synthesis of Ynamines and 
Aminosulfonamides 
 
With the synthesis of the Wieland-Meischer Ketone analogue proving to be caprious, it 
was felt necessary to expand the work of this thesis beyond this previously described 
synthesis. Exploration of recently developed methodology developed within the group 
was undertaken to expand its remit from the synthesis of ynol ethers to ynamines and 
aminosulfonamides. 
 
3.1   Synthesis of Ynol Ethers 
 
Recent work within the Wilden group has focused on the synthesis of ynol ethers 198 
from alkynyl sulfonamides 197 in the presence of potassium tert-butoxide (KOtBu) and 
anhydrous DMF. 137 
 
 
Scheme 51: (a) KOtBu, DMF, trace 
 
Altering the conditions with regards to the solvent and tert-butoxide counterion, did not 
facilitate the synthesis of ynol ether 198.  The trials made concluded that only this metal 
counterion and solvent combination (potassium and DMF) resulted in the ynol ether, 
raising the question; what was special about these conditions.  Initial thoughts were 
based upon the knowledge that over time, DMF slowly decomposes to form carbon 
monoxide and the secondary amine, dimethylamine (DMA) 200.  With the well 
documented employment of secondary amines as organocatalysts, it was necessary to 
investigate whether the decomposition product was behaving in this manner and giving 
DMF its unique properties in this reaction.   
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Employment of an excess of DMA with THF as the solvent did produce the ynol 
product 198, with optimised conditions producing a yield of 85%.   
 
With this reaction displaying attack and substitution of a nucleophilic alkoxy anion at 
the most electron rich alkynyl carbon, mechanistic investigations were conducted. The 
use of continuous-wave electron paramagnetic resonance (cw-EPR) demonstrated the 
existence of an oxygen-centred radical within the reaction mixture. The use of lithium 
or sodium counterions or the absence of amine resulted in a loss of radical signal. This 
spectroscopic observation corresponded to the experiemental observations made when 
these conditions were employed in the reaction. These combined experimental and 
spectroscopic observations have led to the suggestion of a radical species centred in a 
potassium-amine-alkoxide complex 201, which quickly assembles in THF and DMF at 
a rate that is too fast for the radical inhibitor TEMPO to be effective.145  
 
 
Figure 45 
 
 In addition to the interesting mechanistic details associated with this reaction, it has 
also enjoyed a significant degree of scope at both the α and β ends of the alkyne. A 
variety of alkoxide salts have been successfully incorporated into this reaction.  
Methoxide, ethoxide and neopentoxide examples have also been reported via the in situ 
formation of the potassium salt from the reaction of the parent alcohol and either 
potassium metal or potassium hydride.137,145 A variety of ortho, meta and para electron 
withdrawing and electron-donating groups and heterocycles are tolerated at the β end of 
the alkyne; however only aromatic groups result in the formation of an ynol ether.  
Aliphatic examples yield addition products of the butoxide at the traditional β end of the 
alkyne 202.   
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Scheme 53: (a) KOtBu, HNMe2, THF 
 
In the development of this synthetic protocol, this β addition product had been observed 
when standard grade hydrated DMF was employed as the solvent instead of the 
anhydrous form used in the optimised conditions.  Here, the ynol ether was observed 
alongside both the α and β addition products 204 and 205 in a 1:3 ratio.137  
 
 
 
Scheme 54: (a) KOtBu, DMF 
 
Further elaboration has extended the scope beyond that of oxygen examples.  
Employment of potassium hydride with thiols has produced a range of potassium 
thioalkoxide salts, which in the presence of DMA and THF yields the corresponding 
thiol ynol ethers 206 in 32-73% yields. As seen with the alcohol examples, these thiols 
display a wide scope of aliphatic examples but are again limited to the use of aromatic 
alkynyls.138  
 
 
Scheme 55: (a) HSR, KH, HNMe2, THF 
 
With the expansion and success of this area of research into the use of other 
heteroatoms, it was questioned whether this research could be expanded further with the 
employment of amine examples, to yield either the ynamine 209, α-aminosulfonamide 
207 or β-aminosulfonamide 208.  
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Figure 46 
 
3.2   Synthesis of Ynamines and Ynamides 
 
As a handle for further elaboration and synthetic manipulation, ynamines and ynamides 
provide a strongly polarised triple bond due to the electron donating ability of the 
nitrogen, which enables a clear differentiation between the two sp carbons allowing for 
a high degree of regioselectivity.146-149 Despite being a highly reactive species with all 
the inherent advantages such a status brings, these compounds have not enjoyed the 
same widespread utilisation as their related enamine.148-150  
 
 
Scheme 56 
 
In addition and as a consequence of this high reactivity, ynamines have proved to be 
particularly susceptible to hydrolysis, with protonation of the electron-rich alkyne 218 
leading to the highly reactive keteniminium intermediate 211.  Attack of water upon this 
intermediate leads to the corresponding amide, thereby representing a convoluted and 
difficult synthesis for amides 212 in general. 
 
 
Scheme 57 
 
With the example of an ynamide, addition of a simple carbonyl or sulfonamide 
appended to the nitrogen has the advantage of tempering the donating ability of the 
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nitrogen, through resonance delocalization onto the carbonyl or sulfonamide, thereby 
making the alkyne less reactive, less readily hydrolysed and more stable.146,148,149  
 
3.2.1   Synthetic routes to Ynamines 
 
First reported in 1892, it was not until 1958 that an ynamine 215 was isolated and 
characterized by accident from the reaction mixture of phenothiazine 213 and propargyl 
bromide 214.149,151  
 
 
Scheme 58: (a) NaH, xylene, 70% 
 
The first general synthesis of ynamines was reported by Viehe in 1963, which involved 
the exposure of dihalostyrene 216 to the required lithium amide salt at low temperatures 
to produce high yields of the corresponding ynamines.149,152  
 
 
Scheme 57: (a) LiNEt2, diethyl ether, −80 - −20 °C, 86% 
 
The first ynamide synthesis in 1972, again by Viehe et al, employed the chloro-enamide 
219 in an elimination reaction to furnish the ynamide 220 in a 64% yield (scheme 58).  
Although novel in its products, this procedure suffers from a lack of substrate scope, 
which is dependent upon the availability of the starting chloro-enamide.146 
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Scheme 58: (a) 2 eq. NaHCO3, H2O; b) tBuOK, THF, rt 
 
3.2.2   via Elimination 
 
Katritizky et al has employed a double elimination in their synthesis of ynamine 223 
from the α-aminoketone 221, which is treated with triflic anhydride to afford enol 
triflate 222.150 Subsequent treatment with sodium methoxide yields the ynamine 223 in 
a greater than 90% yield.   
 
 
Scheme 59: (a) Tf2O, 2,6-lutidine; (b) NaOMe, CH3CN 
  
A range of aromatic ynamines 227 have been reported deriving from the addition of 
trichloroalkene 225 to the free amine 224.  The subsequent elimination is performed in 
the presence of magnesium to give a yield of 87%.150 
 
 
Scheme 60: (a) cat. TEBACl, NaOH, DMSO; (b)Mg, THF 
 
A number of researchers have investigated the synthesis of “push-pull” ynamines, 
which by possession of an electron-withdrawing group on the β alkynyl carbon, 
promote the conjugation of electrons throughout the moiety (scheme 61). 
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Scheme 61 
 
Bloxham & Dell developed a procedure from alkene 230, which undergoes a 
bromination to afford the α-bromo ester 231.  Subsequent elimination to the “push-pull” 
alkyne 232 occurs upon exposure to potassium tert-butoxide.153,154  
 
 
Scheme 62: (a) Br2, NEt3, DCM; (b) tBuOK, THF, 52% 
 
Hsung et al utilised the brominated enamide 236 (scheme 63), which is derived from the 
reaction of either bromine or NBS with the starting enamide 233.  Here potassium tert-
butoxide was employed as the base for the elimination procedure and yielded the 
ynamide 235 in a range of 72-88% depending upon the nature of R.  Initially the yields 
for this procedure seem positive, however, the preliminary bromination step yields a 
mixture of E and Z isomers in a variety of 1:8 to 1.5:1 ratios and under the conditions 
described here, elimination to afford the ynamide is only successful with the Z 
isomer.148,155,156  
 
 
Scheme 63: (a) Br2 (R=alkyl) or NBS (R = aryl), DCE, reflux; (b) KOtBu, THF, rt 
 
Sáa et al have reported a two-step general route to ynamides 237 from the 
dichloroalkenylsulfonamide 236, which allows for quick generalisation of the β position 
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of the alkyne. Here nbutyl lithium is employed as the base to deprotonate at the α 
position and cause the moiety to undergo an E1cb mechanism to yield the lithium 
acetylide, which can be quenched with a variety of electrophiles.  A number of 
electrophiles have been utilised such as TMS, benzaldehyde, phosphate esters and 
methyl iodide to give a wide substrate scope for the reaction in 73-88% yields.148,157  
 
 
Scheme 64: (a) nBuLi, THF, −78 °C; (b) E+, rt 
 
3.2.3   via Substitution 
 
As expected the substitution pathway employs the displacement of a leaving group on 
the sp hybridized carbon for the required amine to afford the desired ynamine.  One 
important and widely used route to ynamines has been via the use of iodonium salts. In 
work by Stang et al, a range of “push-pull” ynamines were synthesised from the 
corresponding phenyliodonium triflate 238 in an up to 66% yield.158 Although on paper 
this reaction proceeds via substitution of the iodonium salt for the amide ion, it is 
widely believed that instead addition of the amide occurs on the β alkynyl carbon 
resulting in expulsion of iodobenzene and a vinyl carbene, which undergoes a 1,2-shift 
to afford the ynamine 240.150  
 
 
Scheme 65: (a) Et2O, −78 °C, 43-66%; R= TMS, -C(O)Ph, -C(O)tBu, p-Ts 
 
Generally halogens are employed as the leaving group in these reactions with lithium 
amides 239 (scheme 65) as the nitrogen source.159 Tertiary amines have also been 
utilised by Viehe et al in this transformation.160 The difference between the two 
procedures hinges around the temperature with the tertiary amine examples requiring 
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moderate to high temperature (55 °C) and the amide examples low temperatures (−78 
°C). 
 
 
Scheme 66: (a) LiNR2, diethyl ether, −78 °C; (b) NR3, 55 °C 
 
A popular method for the synthesis of ynamides has historically been from the use of 
alkynyl iodonium salts 244, which also enjoy employment in the synthesis of ynamines. 
Here an amide is deprotonated with a suitably strong enough base followed by 
substitution with an alkynyl iodonium salt 244 and has been reported by a number of 
researchers.146,158,161,162 Despite producing ynamides 245 in high yields, the lack of 
availability of the iodonium salts presents the major disadvantage of this procedure.146  
 
 
Scheme 67: (a) nBuLi, toluene, 0 °C, 84%  
 
The turn of the century saw the resurgence of copper catalysis across the breadth of 
organic chemistry and its use in the preparation of ynamides has yielded the most 
efficient procedures.146 In 2003, Hsung et al were the first to employ this catalyst in the 
synthesis of ynamides, providing the “first direct and atom-economical” route to 
ynamides.148 With the use of N,N’-dimethylethylenediamine (DMEDA) as a ligand, 
alkynyl bromides 246 (scheme 68) were coupled with a range of amides 247 with yields 
of up to 85%, however substrate scope and the use of high temperature are the major 
drawbacks with this initial procedure.146,148,163 With the greatest yields being produced 
for oxazolidinones substrates, amides resulted in poor yields, while sulfonamides did 
not result in the desired ynamide under these conditions. 
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Scheme 68: (a) CuCN (5 mol%), DMEDA (10 mol%), K3PO4, toluene, 110 °C 
 
Hsung et al presented an improvement on their original procedure which proved to a be 
a general procedure.  The combination of copper sulfate pentahydrate and 1,10-
phenanthroline alongside potassium phosphate acting as the base proved to be 
successful, although a relatively high temperature of 60-95 °C was required.146,164  
 
Hsung’s second generation catalyst system has been employed in the intramolecular 
ynamide synthesis resulting in macrocycles 250 (scheme 69).148,165 Here the same 
copper sulfate and 1,10-phenathroline catalyst/ligand system were utilised but 
potassium carbonate was employed as the base in these examples resulting in high 
yields up to 96% of the macrocycles 250. 
 
 
Scheme 69: (a) 10 mol% CuSO4.5H2O, 20 mol% 1,10-phenanthroline, 2 eq. K2CO3, toluene, reflux, 96% 
 
An alkynyl bromide 246 is required for all the copper-catalysed procedures described so 
far, which can prove to be difficult to synthesise.  With this in mind, terminal alkynes 
would be the ideal starting material and Stahl et al reported the first copper catalysed 
aerobic oxidative coupling of terminal alkynes 251 with an electron deficient amine. By 
employing a copper chloride catalyst alongside pyridine and sodium carbonate, the 
reaction benefits from a vast reaction scope including sulfonamides, amides, ureas and 
oxazolidinones. Although to ensure the reduction of side products, the use of five 
equivalents of the nucleophile is required.146,148,149,166,167 
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Scheme 70: (a) CuCl2 (20 mol%), O2, pyridine, Na2CO3, toluene, 70 °C  
 
3.2.4   via Isomerisation 
 
Katritzky et al highlight the usability of isomerisation as a synthetic route to ynamines 
with their synthesis beginning from amine 254.  Here amine 254 is exposed to a basic 
mixture of sodium hydride in DMF followed by the addition of propargyl bromide to 
yield 255.  Isomerisation is induced by the mixture of potassium hydroxide and DMSO 
to give the ynamine 256 in a 55-80% yield.148,168  
 
 
Scheme 71: (a) Propargyl bromide, NaH, DMF; (b) KOH, DMSO 
 
Hsung et al has demonstrated the ability of catalytic potassium tert-butoxide to cause 
the isomerisation of propargyl amides 257 to afford the corresponding ynamides 258.156  
 
 
Scheme 72: (a) KOtBu (20 mol%), THF, rt 
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3.3   Reactions of Ynamines and Ynamides 
 
Despite the difficulties in the synthesis of ynamines, the synthetic utility of this 
functionality is demonstrated in the range of reactions that can be undertaken. 
 
3.3.1   Addition Reactions 
 
Given the electron-donating ability of the nitrogen within ynamines, addition reactions 
of electrophiles and nucleophiles occur with a high level of regioselectivity. 
 
Ishihara et al have investigated the manipulation of fluorinated ynamine 259. Exposure 
of the fluorinated ynamine 259 and benzaldehyde 260 to a Lewis Acid leads to the 
formation of amide 261.  The majority of Lewis acids yielded the amide in a high yield, 
with BF3.OEt2 performing the best at 92% and providing a range of aromatic, 
heteroaromatic and alkyl derivatives in high yields.154  
 
 
Scheme 73: (a) BF3.OEt2, MS 4 Å, DCM, 1 h, 92% 
 
A route to α-bromoamide 262 from ynamine 259 is through the use of the renowned 
brominating agent, N-bromosuccinimide (NBS), which can yield the bromoamide 262 
in a 57% yield from an aqueous, room temperature reaction medium.  In addition to 
bromoamide 262, the addition product 263 is also afforded in a 27% yield. Use of a 
mixture of acetonitrile and water as the solvent resulted in a preference for amide 263 
with an 85% yield and a 12% yield of the addition product 288. The use of N-
chlorosuccinimide (NCS) and N-iodosuccinimide (NIS) under the same conditions 
result in the corresponding α-haloamide in an 85% and 80% yields respectively.  Use of 
anhydrous acetonitrile will afford the addition product as the only product with a good 
yield (99-66% depending upon halogen), but as a mixture of geometrical isomers.154  
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Scheme 74: (a) either NXS, MeCN-H2O, rt, 1 h or NXS, anhy. MeCN, MS 4 Å 
 
In this example Hsung and coworkers demonstrate the first stereoselective Ficini-
Claisen rearrangement through the employment of chiral ynamide 264 and allyl alcohol 
264.  In the presence of p-nitrobenzenesulfonic acid (PNBSA), the initial oxygen 
addition of the alcohol onto the α-ynamide carbon, set up the necessary conformation 
for a Claisen [3,3]-sigmatropic rearrangement to yield the amide 267, with high 
diastereoselectivity of the syn conformation in a good 60-86% yield.168 Ynamide 267 
exhibits the use of Sibi’s chiral auxillary,168,169 which had proved to be the best 
auxiliary for this work over others trialed including the Evans auxiliary 270, with 93:7 
ratio of diastereoisomers reported for Sibi’s and 68:32 ratio for Evans.170  
 
 
Scheme 75: (a) PNBSA (0.2 eq.), 80 °C, toluene, 15 h 
 
Building on this work, Hsung extended the application for this protocol by applying it 
to the use of propargyl alcohols 118 instead of allylic ones 265 employed thus far.171 
Here again, a [3,3] sigmatropic rearrangement occurs but with a propargyl alcohol it 
occurs between an alkyne and an alkene, known generally as a Saucy-Marbet 
rearrangement,172 to yield the terminal allene 268, instead of the terminal alkene 267 
seen for the Ficini-Claisen rearrangement.  Again, the use of an ynamide based on 
Sibi’s Auxiliary 264 provided amide 268 in a higher diastereoselectivity when 
compared to the ynamide-Evan’s Auxiliary 269 examples, with the greatest being when 
R was n-butyl yielding the corresponding amide in a 85:15 ratio and a 70% yield.   
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Scheme 76: (a) PNBSA (0.1 eq.), toluene, 80 °C 
 
Alongside the work by Hsung, a number of other groups have investigated the effect of 
metal-catalysed addition reactions of ynamides.  Skrydstrup and coworkers employed 
the use of a gold catalyst to form a mild protocol for the highly regioselective 
hydroamination of ynamides 270 and anilines 271.173 A wide range of both anilines, 
cyclic and acyclic ynamides have displayed excellent yields of between 89-98% and 
excellent regioselectivity for the α position on the ynamide. 
 
 
Scheme 77: (a) (PPh3)AuNTf2 (1 mol%), CH2Cl2, rt, 4 h 
 
Interestingly, Balieu et al have employed an intramolecular radical addition to an 
ynamide 273 to yield the tetrahydroisoquinoline 275.174 Upon subjecting the 
specifically designed ynamide 273 to both a radical initiator, AIBN, and carrier, 
tributyltin hydride, a 6-exo-dig radical cyclisation occurs onto the α alkynyl carbon 
followed by migration of the trifluoroacetyl group to yield 275 in a 49% yield. 
 
 
Scheme 79: (a) AIBN, Bu3SnH, benzene, 80  °C; (b) 1M NaOH 
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Disappointingly, this procedure did not show great substrate scope; however, it has 
displayed the ability to form two fused rings from ynamide 276.  Under the same 
reaction conditions as above, this substrate undergoes the same 6-exo-dig cyclisation 
followed by a 6-endo-trig cyclisation to yield 278, although with a reduced yield of 
30%.174  
 
 
Scheme 80: (a) AIBN, Bu3SnH, benzene, 80 °C; (b) 1M NaOH 
 
3.3.2   Cycloaddition Reaction 
 
Cycloadditions are a key group of reactions for this functional group and have been 
used to synthesise nitrogen containing heterocycles.175 The synthesis of pyridine is a 
good example of this. Here the unsubstituted triazine 279 is coupled with ynamine 280 
in a Diels-Alder reaction to yield the pyridine 281 with loss of nitrogen and a clean 
regioselectivity with the cycloaddition occurring across the N1/C4 atoms of the 1,2,3-
triazine 279.175  
 
 
Scheme 81: (a) 60 °C, CHCl3, 64-93% 
 
Pirrung et al have demonstrated the ability of an alkynyl pyrrole, along with other non-
functionalised alkynes and ynol ethers, to undergo [2 + 1] cycloadditions with rhodium 
carbenoids to form the cyclopropene 284.  Rearrangement of the intermediate will form 
the fused furan 285 with the pyrrole functionality in the 2 position.  A modest 40% 
yield was reported for this process, which was among the lowest compared to the other 
reported analogues with the highest being the ethoxy analogue 286 at 79%.176 
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Scheme 82: (a) Rh(OAc)2 
 
Hsung et al have employed a [2+2] cycloaddition of an ynamine 256 and an aldehyde 
287 to achieve a two-carbon oxidative homologation of the aldehyde.  Here the use of 
catalytic boron trifluoride diethyl etherate sees the cycloaddition and subsequent 
rearrangement occur to afford the unsaturated amide 288 in a 58-91% yield and a 20:1 
preference for the E isomer over Z.177 Subsequent treatment with lithium hydroxide 
gives the acid hydrolysis product 290 in a 90% yield alongside the amine 254. 
 
 
Scheme 83: (a) cat.BF3.OEt2, DCM or toluene, −78 °C, 5-15 h; (b) 1M LiOH, THF.H2O, rt, 24 h 
 
Tam et al reported the first ruthenium catalysed [2+2] cycloaddition by employing 
norbornene 291 and acyclic ynamides 292 as their model system.148,178 A range of 
yields were reported for the ynamide derivatives peaking at 97% when both R1 and R2 
are phenyl.  Under these conditions, an increase in steric bulk on the nitrogen led to a 
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reduction in the yield of the addition product 293.  While this feature was replicated at 
the other end of the alkyne, the presence of an electron withdrawing aromatic group in 
the R2 position also reduced the yield of 293, although not as significantly as when 
propargylic alcohols or propargylic silyl ethers were present.  
 
 
 
Scheme 84: (a) CpRuCl(COD), THF, 60 °C, 72 h 
 
Like synthetic routes and addition reactions previously, Hsung has been active in 
researching the cycloaddition reactions of ynamides as well. In this example, the use of 
Lewis acid, boron trifluoride diethyl etherate, catalyses the intramolecular [2+2] 
cycloaddition between the ynamide and carbonyl functionalities within 294, thereby 
quickly yielding the fused 5,4 ring system seen in 295.  However like Hsung’s previous 
work177  noted in section 3.2.3.2, this compound is not the product of the reaction, as it 
quickly rearranges to form the unsaturated amide 296 in around 15 mins at room 
temperature.  A range of yields were reported most within 65-88%, while significant 
reductions were observed when the connecting aliphatic chain was increased, to give a 
resulting ring size of 7 and when the oxazolidinone was replaced by a benzyl protected 
sulfonamide with yields of 35 and 33% respectively.  Interestingly, this reaction was 
also successful in the presence of a Brønsted acid with PNBSA affording a similar yield 
of the aldehyde analogue of ynamide 294 (74%), however, a significant increase in acid 
and reaction time was required (up to 1.25 eq. and 30 mins).  In contrast, triflimide, 
HNTf2, was employed with the same catalyst loading and reaction time as the Lewis 
acid, with only a slight drop in yield at 66%.179  
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Scheme 85: (a) BF3.OEt2 (0.25 eq.), DCM, rt, 15 mins 
 
In addition to being a [2+2] cycloaddition, the ynamide 297 example is also an example 
of a hetero-enyne ring closing metathesis, which was an extension of Hsung previous 
work on the more traditional Grubbs metathesis of ynamides.156 Here ynamide 297 is 
exposed to Grubbs’ second generation catalyst forming the amidodiene 298 in high 
yields of 83-87%.  Further work demonstrated that in the presence of dienophiles, these 
products can undergo a Diels-Alder reaction to form the 6,6 bicycle 299 in an 80% 
yield, although with disappointing diastereoselectivity. 
 
 
Scheme 86: (a) Grubbs II, toluene, 75-80 °C; (b) dimethyl acetylenedicarboxylate, toluene, 150 °C  
 
Compared to other heteroalkynes, ynamides possess the unique ability to be tethered to 
two alkynyl substituents, thereby allowing a tandem ring closing metathesis to occur.  
Here again, Grubbs’s second generation catalyst provided cyclised products 301 and 
302 in a combined 77% yield with a 1:1 ratio of products.156  
 
 
Scheme 87: (a) Grubbs II (10 mol%), toluene, 75 °C, 12 h  
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Direct Diels-Alder or [4+2] cycloaddition reactions have been reported on ynamide 
species with the first intramolecular example was demonstrated by Witulshi et al, 
yielding diene 304 in a 54% yield.180  
 
 
Scheme 88: (a) 80 °C, benzene 
 
3.3.3   Functionalisation Reactions 
 
As expected, by possession of an alkyne in their structure, ynamides are perfectly set up 
to undergo Sonogashira couplings and again, Hsung has led the way in the extension of 
this palladium coupling reaction to ynamides.181 Here exposure of terminal alkyne 305 
to an aromatic iodide species in the presence of both palladium and copper catalysts led 
to the formation of ynamide 306 in yields ranging from 44% to 96%.  With both 
electron-withdrawing and electron-donating groups being tolerated, heteroaromatics 
also proved to be successful in this coupling reaction with the 4-anisyl analogue 
producing the highest yield.  Alkene derivatives were also afforded, although 
significantly lower yields were produced in the 31-42% range. 
 
 
Scheme 89: (a) Ar-I, Pd(PPh3)4 (3.3 mol%), CuI (1.5 mol%), NEt3:Toluene (2:1), 65 °C 
 
Saá et al employed palladium catalysts in a coupling between an aryl iodide and an 
ynamide 307, which possesses a zinc bromide at the β position of the alkyne in a 
Negishi style coupling.182 This coupling proceeds best when an electron-withdrawing 
group or an electron poor heteroaromatic is used as the reagent with used between 92-
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42%.  Electron-donating group produced a significant reduction with yields of 25% 
reported with o-iodoanisole. 
 
 
Scheme 90: (a) Ar-H, Pd2dba3(5 mol%), PPh3 (20 mol%), rt, 2 h 
 
3.3.4   Use in Total Synthesis 
 
In addition to the many examples of methodological uses of ynamines, they have also 
played a role in the total synthesis of the natural product (+)-(6R)-hydroxybrefeldin A 
313.  Here the carboxylic acid 309 reacts with the α carbon of the keto-ynamine 310 to 
yield the intermediate 311, which will rearrange to form the amide 312 in situ in a 
quantitative yield.87,183,184  
 
 
Scheme 91: (a) THF, −50 °C, 1 h 
 
Hsung et al have employed ynamides in the synthesis of two related natural products, 
10-desbromoarborescidine A 316 and 11-desbromoarborescidine C 317.185 Both 
synthesises use the same key acid catalysed Pictet-Spengler transformation from the 
ynamide 314 to produce the tosylated piperidine 315 within 5 minutes in a 56% yield 
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for desbromoarborescidine A and 67% for desbromoarborescidine C synthesises.  A 
further two and five steps were required to produce the target molecules 316 and 317 
respectively.   
 
Scheme 92: (a) PNBSA (15 mol%), toluene, 90 °C, 5 mins X = Cl for 10-desbromoarborescidine A; X =  
OBn for 11-desbromoarborescidine C 
Alongside co-workers, Cossey & Meyer employed palladium coupling methodology on 
ynamides to exert an intramolecular cyclisation in the synthesis of lennoxamine 321.186 
The key Heck-Suzuki-Miyaura domino reaction resulted in the core isoindolinone of 
lennoxamine 321 with a 77% yield and an E:Z ratio of 85:15. 
 
Scheme 93: (a) Pd(OAc)2 (5 mol%), PPh3 (10 mol%), aq. NaOH, THF, reflux 
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3.4   Aminosulfonamides and Peptidomimetics 
 
Aminosulfonamides have received a significant but not comprehensive level of 
attention in the literature, particularly within the field of peptidomimetics. 
Peptidomimetics or pseudopeptides seek to overcome the limitations of the peptide 
bond by substituting the amide functionality for an isostere, which can mimic the 
natural peptide in terms of the geometry, polarity and acidity.187-190 Natural carbon 
based peptides are highly susceptible to hydrolysis and attack by proteases and one field 
of thought seeks to replace the bond with a heteroatom equivalent such as 
phosphonates, sulfonates and sulfonamides.   
 
The advantage of employing a sulfonamide as a peptidomimetic is firstly its possession 
of a distorted tetrahedral geometry, which is similar to that of the tetrahedral 
intermediate that is formed during cleavage of the amide bond during attack by 
proteases and hydrolysis.191-194 This geometry in sulfonamides means that it is no longer 
favourable for protease and water attack, thereby making this pseudopeptide bond 
resistant to this form of attack.191,194  
 
Secondly, the acidity of the proton on the nitrogen is significantly greater in a 
sulfonamide compared to the native peptide, with pKa of around 8 and 25 
respectively.192,194 This increase in acidity will also increase the polarity of the 
sulfonamide and the hydrogen-bond donating abilities of its N-H. Although as hydrogen 
bond acceptors, sulfonamides do not compare favourably to amides, displaying acceptor 
levels below that of amides in the same range as esters.187,192  
 
Reports within the literature have highlighted a significant difference in the synthesis 
and stability of the two analoguous aminosulfonamides, the α analogue 322 or in the β 
analogue 323. 
 
 
Figure 46 
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Attention has been focused upon β-aminosulfonamides with minimal advancement 
being made for the synthesis and employment of the α-analogue.  This is somewhat 
surprising given that the α-configuration most closely resembles that of the natural 
amino acid that the peptidomimetics seeks to mimic.  However, literature reports argue 
that the α-configuration 324 leads to an unstable moiety that is liable to fragmentation, 
expelling the sulfonamide unit 326 and the corresponding amine 325.192,195-197 This 
fragmentation is most notably observed when the free α-aminosulfonamide is 
isolated,192 but they can be observed when in a non-polar organic solvent.195  
 
 
 
Scheme 94 
 
Gilmore et al first reported the attempted synthesis of α-aminosulfonamides based on 
glycine and phenylalanine via a Curtius rearrangement, raising the question of their 
stability.196,197 Paik and White195 employed the same key Curtius rearrangement step to 
synthesise the alanine based α-amidosulfonamide 331.  In this instance, despite an 
inability to isolate sulfonamide 330, the compound could be identified while in a non-
polar organic solvent.  Exposure to polar solvents and water lead to fragmentation of the 
compound.195 
 
 
Scheme 95: (a) tButylamine; (b) N2H4; (c) HNO2; (d) heat; (e) MeOH 
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Despite these early negative reports of instability of α-aminosulfonamides, this 
functionality has been intergrated into larger molecules such as compounds 332198and 
333,199 which demonstrate that this functionality has the ability to be stable.    
 
 
Figure 47 
 
 
However the synthesis of both these compounds do not display novel chemistry.  
Triazole 332 is synthesised via click chemistry from the azide 335, which is installed by 
a substitution of the corresponding bromide 334.198 
 
 
Scheme 96: (a) NaN3, DMF, 79% (b) CuI, DIPEA, sodium L-ascorbate, DMF, 23% 
 
With the indole example 333, chloromethanesulfonyl chloride is added to indole 338 to 
afford the sulfonamide 339.  Cyclisation and formation of the α-aminosulfonamide 
functionality is achieved with the use of sodium hydride and DMF.199 
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Scheme 97: (a) pyridine, DMAP, DCM, 92% (b) NaH, DMF, 41% 
 
Work by Adams et al again shows that the α-aminosulfonamide functionality is stable 
when tethered in a larger molecule 343.  In this example it is enclosed within a 6 
membered ring, with the amino portion occupying the connecting position between the 
two heterocycles.  Again simple chemistry is employed to achieve this.200  
 
Scheme 98: DIPEA, DCM, −78 °C (b) DMF, EtOH, DIPEA, microwave 
 
Although routes to β-aminosulfonamides have been more fruitful than those to their α 
counterparts, they still don’t display a succinct and noteworthy synthesis.  Instead 
several multi-step synthesises have been documented.  Within our group, a β-
aminosulfonamide has been previously synthesised in the synthesis of 2,4-oxazoles.201 
In this example, vinyl sulfonamide 344 undergoes bromination, followed by elimination 
to afford the bromo vinyl sulfonamide 345.  Ammonia is added via a 1,4-addition to 
yield the β-aminosulfonamide 346.   
 
Scheme 99: (a) Br2 (b) NEt3 87%; (c) (NH4)2CO3, NMP, 60 °C, 80% 
 
However further variation of the aminosulfonamide to include a phenyl group in the β 
position 349 was unsuccessful.  A Heck coupling of vinyl sulfonamide yields the 
conjugated sulfonamide 347, which can undergo the same bromination and elimination 
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previously used.  However the addition of ammonia was unable to be successfully 
achieved under numerous conditions trialed.201 
 
 
Scheme 100: (a) PhI, PdCl2, NMP, 120 °C, 70% (b) Br2 (c) NEt3, 0 °C, DCM, 92% (d) (NH4)2CO3, 
NMP, DMF, TNF, MeOH 
 
Synthesis of 2,4-oxazole requires a further two steps from this aminosulfonamide 
involving firstly acylation with a variety of acyl chlorides to yield the 
amidosulfonamide 350.  Treatment of this amidosulfonamide with sodium tert-butoxide 
affords the oxazoles 351 in a range of yields 50-92%.201 
 
 
Scheme 101: (a) RCOOCl, DCM 55-93% (b) NaOtBu, DMF 50-92% 
 
Two routes have employed the N-phthalimido protecting group in the synthesis of β-
aminosulfonamides, which have displayed medicinal properties.  Work by Humljan et 
al employed this group in the protection of L-alanine 352 affording 353, which 
undergoes subsitition of the alcohol for a thiol 354 via mesylation. Further manipulation 
yields the sulfonyl chloride 355.202  
 
 
Scheme 102: (a) NaBH4/I2, THF, 0 °C-reflux (b) MeOH, 60% (c) phthalic anhydride, 140 °C, 86% (d) 
MsCl, NEt3, DCM, 0°C-rt, 96% (e) Cs2CO3, HSAc, DMF, 50 °C, 82% (f) H2O2, HOAc, rt (g) Pd/C (h) 
SOCl3, reflux, 85% 
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Sulfonyl chloride 355 is coupled with the methoxy protected glutamic acid to yield the 
β-aminosulfonamide 356.  A further two steps enables deprotection of the phthalimide 
group and then addition of the sulfonamide group gives a β-sulfonopeptide inhibitor.  
However these compounds did not significantly inhibit the enzyme MurD.202 
 
 
Scheme 103: (a) HCl.D-Glu(OMe)2, NEt3, DCM, 0 °C, 75% (b) NH2NH2, H2O, EtOH, rt (c) RSO2Cl, 
NEt3, DCM, 0 °C-rt, 30% 
 
 
The second route by Singhamahapatra et al sees the synthesis of functionalised vinyl 
sulfonamide 360, which is coupled with the phthalimide protecting group to yield the β-
aminosulfonamide in a 96% yield.  
 
 
Scheme 104: (a) Bromoacetic acid tert-butyl ester, K2CO3, MeCN, 0 °C-rt, 24 h (b) 2-
chloroethanesulfonyl chloride, DIPEA, DCM, 0 °C-rt, 24 h, 70% (c) MeCN, 60 °C, 24 h, 96% 
 
Although compound 361 hasn’t been tested on a medicinal target, its possession of the 
phthalimide protecting group enables it, like the previous example, to be employed in 
the synthesis of longer chain peptide mimics.203 
  
In addition to the synthesis of peptidomimetics, β-aminosulfonamides have also been 
incorporated into compound 362, which shows promise as a lead scaffold in the 
development of new anti-Mycrobacterium tuberculosis H37Rv agents.204  
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Figure 47 
 
Further to the work the conducted on aminosulfonamides in the medicinal chemical 
setting, there is evidence of a β-aminosulfonamide, based on phenylalanine, being used 
as an organocatalyst for the aldol reaction between cyclohexanone 364 and 
nitrobenzaldehyde 363.  With a catalyst loading of 10 mol%, the product 365 is 
afforded in a 82% yield, with 92%ee and an anti:syn ratio of 80:20.205  
 
 
Scheme 105: (a) cat 366 (0.1 eq), brine, rt, 20 h, 82% 
 
3.5   Synthetic Investigations 
 
The immediate drive of this work was to extend the methodology developed within the 
group into the synthesis of ynol ether to form, ideally, ynamines.137 With both α and β 
addition products being reported, it was expected that if an ynamine was not observed, 
the nitrogen analogues of these alternative products might be. Although not the goal of 
this work, the presence of either of these addition products would provide an excellent 
opportunity for their employment in ether the synthesis of heterocycles or as 
peptidomimetics and represent a novel and hopefully versatile synthetic route towards 
either of these compounds. 
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With this in mind, investigations began with the use of N-methylaniline 367, which was 
exposed to potassium hydride to form the potassium amide salt.  Upon complete salt 
formation, dimethylamine and THF was added to the reaction mixture followed by the 
swift addition of alkynyl sulfonamide 197 at −78 °C, pleasingly producing the α 
addition product 368 in a 52% isolated yield after a reaction time of 15 mins.   
 
 
Scheme 106: (a) KH (8 eq.), N-methylaniline 367 (4 eq.), THF; (b) HNMe2 (2 M in THF, 4 eq.) 
 
With the α configuration of 368 confirmed by HMBC NMR, the product 368 from this 
reaction possesses the rare functionality of an α-aminosulfonamide in a significant 
yield.  
 
Evaluation of the reaction conditions to ensure the existing ynol ether conditions were 
optimal and a variety of different bases were trialed, instead of the previously successful 
potassium hydride. The employment of LDA and sodium hydride did not yield a 
successful reaction, while butyl lithium resulted in the production of the β-
aminosulfonamide 369, alongside the ketosulfonamide 370 in 20% and 11% yields 
respectively 
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Base Product Yield (%) 
KH 
 
52 
NaH - 0 
LDA - 0 
BuLi 
 
 
 
20 
 
11 
Table 6: (a) base, THF; (b) HNMe2 
 
This short survey of bases collaborated the results shown within the ynol ether studies 
and subsequent mechanistic studies that the potassium counterion is instrumental in this 
reaction pathway. 
 
Keeping the reaction conditions the same; the next point of variation that was 
investigated was the nature of the amine species. With the initial focus on the alkyl 
nitrogen tether, represented up to now as a methyl, two replacements were employed. 
These replacements took the form of acyl and benzyl tethers from the commercially 
available N-acetylaniline 371 and N-benzylaniline 372, investigating the effects of an 
electron-withdrawing group and steric bulk respectively.  Positively, the use of 
increased steric bulk on the amine did not have a detrimental effect on the desired 
reaction yielding 32% of corresponding α-aminosulfonamide 374.  However, the 
presence of the acetyl did have a detrimental effect on the reaction with no identifiable 
products being produced.   
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Scheme 107: (a) KH, THF; (b) HNMe2 
 
The next question that was raised was regarding whether the phenyl functionality was 
required or if the reaction could be extended to completely aliphatic amines or amides.  
Here three different amines were employed and in all examples both potassium and 
lithium counterions were trialed.  The amines utilised here were pyrollidin-2-one 375, 
pyrollidine and diisopropylamine.  Under the reaction conditions previously detailed, 
pyrollidin-2-one 375 was the only aliphatic amine to react to yield the β-addition 
product 376, when potassium was used as the counterion in a good yield of 71%. When 
the counterion was lithium as expected no product was formed.  However, removal of 
the electron-withdrawing group on the amine did not afford either α or β products, with 
both pyrollidine and diisopropylamine yielding no reaction under both conditions.   
 
 
Scheme 108 
 
Although pyrollidinone 375 disappointingly yielded the β-aminosulfonamide 376, it did 
do so in a high yield and was the only amine, aromatic or aliphatic, to react with the 
tert-butyl alkynyl sulfonamide 202,218 despite with a low yield (23%) of 377. 
 
 
Scheme 109 
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With the mechanistic work conducted on the ynol ether synthesis, there is substantial 
evidence that both the ynol ether and α addition products are the result of a radical 
mechanism,145 while β addition is the product derived from the expected nucleophilic 
mechanism.  The reactive radical species with the oxygen examples, as described 
previously in section 3.1, sees hydrogen bonding between the two lone pairs of oxygen 
with protons on dimethylamine, which in turn, bonds to the potassium counterion to 
form a 6 membered ring 201, thereby stabilising the radical charge. When an aliphatic 
amine is introduced to these reaction conditions, this 6 membered ring cannot be formed 
due to lack of the two lone pairs 378 (fig. 48) meaning that the radical mechanism 
cannot be supported, allowing for nucleophilic substitution and β addition.  
 
 
Figure 48 
 
However, when aniline is employed, the phenyl ring allows for resonance and the 
dispersion of the radical charge into the aromatic ring.  In turn this gives the nitrogen an 
additional electron, creating two lone pairs of electrons and potentially mimicking 
oxygen 201.  This suggests that the radical mechanism can now proceed and α addition 
is observed.   
 
 
Scheme 110 
 
The last point of variation that was investigated was the substitution on the aniline.  
Firstly, monomethylation of suitable anilines was required and methyl iodide, alongside 
potassium carbonate were employed as the reaction conditions for this transformation.  
Although successful in providing the monomethyated anilines, this procedure did result 
in the mono-product being the minor product, while the di-methylated anilines were the 
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major product, which did result in significantly lower yields of monomethylaniline 
(table 7). 
 
 
Starting Material Product Number Yield (%) 
  
381 15 
  
382 17 
  
383 31 
  
384 27 
Table 7 (a) MeI, K2CO3 
 
Upon subjecting anilines 381 - 384 to the reaction conditions, it surprisingly did not 
result in the corresponding α-aminosulfonamide and produced an inseparable and 
unidentifiable reaction mixture.   
 
The last aromatic amine to be employed was indole, which gave a high yield of the 
aminosulfonamide 90%.  However proton NMR showed that this was a mixture of α 
and β aminosulfonamides in a 386:387 ratio (2:1). 
 
 
Scheme 111: (a) KH, THF (b) HNMe2 (2M in THF) 
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With the disappointing results seen when substituents were added to the aromatic ring, 
this observation suggests that although the phenyl analogue 368 is stable and can be 
isolated, it is a stability, which is finely balanced, probably between the aniline and the 
styrene moiety on the α carbon.  The slight changes made by the introduction of both 
electron-withdrawing and electron-donating groups have the ability to disrupt this and 
the stabilisation of the radical species.  Potentially, this causes these products to move 
towards instability and fragmentation, although no fragmentation products were 
observed from the reaction mixtures.   
 
3.6   Conclusion and Further Work 
 
Despite the negative attention within the literature towards α-aminosulfonamides, this 
work has overturned this thought by successfully synthesising and isolating an α-
aminosulfonamide; a feat, which has not been as yet reported within the literature. 
Although the brief investigations so far have failed to extend the radical scope past that 
of the aniline example, thereby suggesting that minor changes to the electronic make up 
of the phenyl ring can disrupt the finely balanced nature of the reactive radical species 
389. 
 
 
Figure 49 
 
Further work in this area should firstly investigate the mechanistic detail of this reaction 
and highlight its similarities and potential differences with regard to the oxygen 
analogues.  From these results, it should be possible to have a clearer idea of what 
substituents could be add to the phenyl ring to ensure maximum yield and stability of 
the product.  
 
Of further interest would be the potential to employ these structures in the development 
of a peptidomimetics, which could more closely mimic the natural amino acid 
arrangements.  The α styrene moiety in particular allows for the potential for further 
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elaboration and manipulation to provide further functionality, which could be of benefit 
for peptidomimetic and drug development. 
4.   Experimental
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4.   Experimental 
 
All reactions were carried out at room temperature, under standard atmospheric pressure 
with stirring, unless otherwise stated. All reactions involving moisture-sensitive 
reagents were carried out under an argon atmosphere, using standard vacuum line 
techniques and glassware that was flame dried and cooled under argon before use. 
Anhydrous solvents were used following purification from an Anhydrous engineering 
(USA) system after drying over alumina granules, with the expection of anhydrous 
DMF, which was purchased from suppliers and used without further purification. 
Petroleum ether used was from the 40-60 ˚C.  All other solvents and reagents were used 
as supplied without prior purification, unless otherwise stated. Petroleum ether used  
 
Column chromatography was carried out using BDH (40-60 µm) silica gel and 
analytical thin layer chromatography was carried out using Merck Keiselgel aluminium-
backed plates coated with silica gel. Plates were visualised using combinations of ultra-
violet light (254 nm) and chemical stains (phosphomolybdic acid and potassium 
permanganate). All yields are quoted as isolated yields. 
 
Melting points were determined using a Gallenkamp apparatus and are uncorrected. 
Infrared (IR) spectra were recorded on a Perkin-Elmer 1605 Fourier transform 
spectrometer or a Perkin-Elmer spectrum 100 FT-IR spectrometer as thin films.  
 
1H NMR spectra were recorded at 400, 500 and 600 MHz on a Brüker AMX400, Brüker 
AMX500 and Brüker AMX600 spectrometers respectively, at ambient temperatures in 
the stated solvent using residual protic solvent CHCl3 (δ = 7.26 ppm, s) or DMSO (δ = 
2.56 ppm, qn) as the internal standard. Chemical shifts are quoted in parts per millon 
(ppm) using the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), 
qn (quintet), m (multiplet), br (broad) or a combination of these. Chemical shifts (δ) are 
quoted to 2 decimal places and coupling constants (J) are quoted to 1 decimal place, 
with coupling constants being measured in Hertz (Hz). 13C NMR spectra were recorded 
at 100, 125 and 150 MHz on a Brüker AMX400, Brüker AMX500 and Brüker 
AMX600 spectrometers respectively, at ambient temperature in the stated solvent using 
4.   Experimental
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the central reference of CHCl3 (δ = 77.0 ppm, t) or DMSO (δ = 39.52 ppm, septet) as 
the internal standard.  
 
High and low resolution mass spectrometry were recorded by the Mass Spectrometry 
department at the Department of Chemistry, University College London using a VG70 
SE operating in modes, EI or CI depending on the sample. 
 
2-Methylcyclohexan-1,3-dione 390 206 
 
 
 
To a solution of cyclohexan-1,3-dione (10.0 g, 89.2 mmol) in 5 M sodium hydroxide 
aqueous solution (20 mL), methyl iodide (11.2 mL, 178.4 mmol) was added and stirred 
at 65 °C for 18 h.  The reaction mixture was cooled to room temperature and the solid 
was filtered to afford the title compound (8.73 g, 78%) as a colourless solid, mp 195-
198 °C (lit219 value 198-200 °C); IR νmax/cm-1 (film) 3428.6, 2950.6, 2887.9, 2595.1, 
2457.1, 1645.7, 1568.6; 1H NMR (DMSO – D6, 400 MHz, ppm) δH 2.29 (4H, t J = 6.3 
Hz, CH2), 1.79 (2H, qn, J = 6.8 Hz, CH2), 1.53 (3H, s, CH3); 13C NMR (DMSO-D6, 150 
MHz, ppm) δC 210.4 (s), 198.1 (s), 55.7 (t), 36.4 (t), 24.1 (q), 20.6 (t); LCMS (EI) m/z 
126 (100%), 98 (85), 83 (30); HRMS (EI) C7H10O2 [M+] requires 126.06753, found 
126.06699. Data consistent with literature values.206  
 
2-Methyl-2-(3-oxobutyl)cyclohexane-1,3-dione 39 40 
 
 
 
Freshly distilled methyl vinyl ketone (2.20 mL, 27.03 mmol) was added to a mixture of 
2-methyl-1,3-cyclohexadione 390 (3.10 g, 24.6 mmol) and triethylamine (0.034 mL, 
0.25 mmol) and stirred at room temperature for 18 h.  The crude product was purified 
by column chromatography (25% ethyl acetate:petroleum ether) to afford the title 
compound (2.78 g, 58%) as a pale yellow oil; IR νmax/cm-1 (film) 2964.4, 2254.3, 
OH
O
O
O
O
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1715.2, 1691.6; 1H NMR (CDCl3, 600 MHz, ppm) δH 2.74 (2H, ddd, J = 15.7, 8.9 & 5.4 
Hz, CH2), 2.62 (2H, ddd, J = 15.7, 8.9 & 5.4 Hz, CH2), 2.33 (2H, t, J = 7.9 Hz, CH2), 
2.09 (3H, s, CH3), 2.05-2.02 (3H, m, CH2 & CHH), 1.93-1.86 (1H, m, CHH), 1.23 (3H, 
s, CH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 210.1 (s), 207.6 (s), 64.5 (s), 38.4 (t), 
37.8 (t), 30.0 (q), 29.5 (t), 20.2 (q), 17.6 (t); LCMS (EI) m/z 196 (85%), 178 (55), 169 
(15), 156 (80), 139 (35), 126 (65), 111 (100), 97 (65), 81 (30), 69 (50); HRMS (EI) 
C11H17O3 [M]+ requires 196.10994, found 196.10942. Data consistent with literature 
values.65  
 
8a-Methyl-3,4,8,8a-tetrahydronaphthalene-1,6(2H, 7H)-dione 34 
 
 
 
L-Proline (0.015 g, 0.10 mmol) was added to a solution of triketone 39 (0.20 g, 1.02 
mmol) in DMSO (1 mL) and stirred at room temperature.  After 72 h, the reaction 
mixture was diluted with water (5 mL) and the aqueous layer was extracted with ethyl 
acetate (3 x 5 mL).  The combined organic layers were washed with brine (5 mL) and 
dried (MgSO4), filtered and concentrated in vacuo to afford the crude product, which 
was purified by column chromatography (40% ethyl acetate:petroleum ether) to afford 
the title compound (0.018 g, 9%) as a colourless oil; IR νmax/cm-1 (film) 2931.8, 2349.5, 
1712.4, 1676.8, 1619.4; 1H NMR (CDCl3, 600 MHz, ppm) δH 5.85 (1H, s, C=CH), 
2.75-2.68 (2H, m, CH2), 2.53-2.42 (4H, m, 2 x CH2), 2.17-2.09 (2H, m, CH2), 1.75-1.65 
(2H, m, CH2), 1.44 (3H, s, CH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 211.2 (s), 198.5 
(s), 171.4 (d), 125.9 (s), 51.9 (s), 37.8 (t), 33.7 (t), 31.9 (t), 29.7 (t), 23.5 (q), 23.0 (t); 
LCMS  (CI+-methane) m/z 179 (100%), 161 (90), 149 (15), 137 (50), 122 (15), 112 (5), 
97 (5), 85 (10), 79 (5), 71 (15); HRMS (CI+-methane) calc’d for C11H15O2 [M+H]+ 
179.10720 found 179.10673.  
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Methyl-3-(2,5-dimethyl-6-oxocyclohex-1-en-1-yl)propanoate 102 
 
 
 
Dimethylhydrazine dihydrochloride (0.013 g, 0.010 mmol) was added to a solution of 
triketone 39 (0.20 g, 1.02 mmol) in methanol (2 mL) and stirred at 70 °C for 6 h.  After 
removal of the solvent in vacuo, the resulting residue was purified by column 
chromatography (100% dichloromethane) to afford the title compound (0.17 g, 81%), as 
a colourless oil; IR νmax/cm-1 (film) 2930.7, 1732.5, 1662.0, 1633.2, 1452.8, 1375.2; 1H 
NMR (CDCl3, 600 MHz; ppm) δH 3.64 (3H, s, OCH3), 2.59 (2H, qt, J = 15.9 & 7.9 Hz, 
CH2), 2.44-2.38 (1H, m, CH), 2.33 (2H, t, J = 7.9 Hz, CH2), 2.32-2.25 (2H, m, CH2), 
1.98 (1H, dq, J = 13.6 & 4.9 Hz, CH), 1.94 (3H, s, CH3), 1.68-1.61 (1H, m, CH), 1.11 
(3H, d, J = 6.7 Hz, CH3); 13C NMR (CDCl3, 150 MHz, ppm) δC  201.1 (s), 173.9 (s), 
155.4 (s), 133.2 (s), 51.6 (q), 40.8 (d), 33.2 (t), 32.2 (t), 30.2 (t), 21.4 (t), 21.9 (q), 15.6 
(q); LCMS (EI) m/z 210 (35%), 179 (35), 151 (25), 150 (100), 140 (43), 125 (27), 109 
(10), 108 (34), 85 (37), 81 (15); HRMS (EI) C12H20O3 [M+] requires 210.12505, found 
210.12422. Data consistent with literature values.64  
 
Ethyl-3-(2,5-dimethyl-6-oxocyclohex-1-en-1-yl)propanoate 103 
 
 
 
Dimethylhydrazine dihydrochloride (0.013 g, 0.01 mmol) was added to a solution of 
triketone 39 (0.20 g, 1.02 mmol) in ethanol (2 mL) and stirred at 70 °C for 6 h.  After 
removal of the solvent in vacuo, the residue was purified by column chromatography 
(100 % dichloromethane) to afford the title compound (0.094 g, 42%) as a yellow oil; 
IR νmax/cm-1 (film) 2927.5, 1737.6, 1662.5, 1631.7, 1455.6, 1379.4; 1H NMR (CDCl3, 
600 MHz, ppm) δH 4.08 (2H, q, J = 7.2 Hz, CH2), 2.59 (2H, qt, J = 13.7 & 9.2 Hz, 
CH2), 2.44-2.37 (1H, m, CH), 2.33-2.26 (4H, m, 2 x CH2), 1.98 (1H, dq, J = 13.7 & 4.7 
Hz, CH), 1.94 (3H, s, CH3), 1.65 (1H, s, CH), 1.23 (3H, t, J = 7.2 Hz, CH3), 1.11 (3H, 
d, J = 6.8 Hz, CH3); 13C NMR (CDCl3, 150 MHZ, ppm) δC 201.1 (s), 173.5 (s), 155.4 
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(s), 133.2 (s), 60.3 (t), 40.8 (d), 35.7 (t), 32.3 (t), 30.2 (t), 21.4 (t), 19.8 (t), 15.6 (q), 14.3 
(q); LCMS (EI) m/z 225 (15%), 224 (100), 179 (15), 178 (23), 150 (12), 108 (10); 
HRMS (EI) C13H20O3 [M+] requires 224.14070, found 224.13968. 
 
Isopropyl-3-(2,5-dimethyl-6-oxocyclohex-1-en-1yl)propanoate 104 
 
 
 
To a solution of triketone 39 (0.20 g, 1.02 mmol) in isopropanol (2 mL), 
dimethylhydrazine dihydrochloride (0.013 g, 0.01 mmol) was added and stirred at 70 °C 
for 18 h.  After the solvent was removed in vacuo, the residue was purified by column 
chromatography (15 ethyl acetate: petroleum ether) to afford the title compound (0.22 g, 
92%) as a colourless oil; IR νmax/cm-1 (film) 2979.4, 2932.1, 1726.6, 1660.7, 1632.9; 1H 
NMR (CDCl3, 600 MHz, ppm) δH 4.90 (1H, septet, J = 6.3 Hz, CH(CH3)2), 2.55 (2H, 
qt, J = 13.7 & 7.6 Hz, CH2), 2.41-2.34 (1H, m, CH), 2.29-2.24 (4H, m, 2 x CH2), 1.95 
(1H, dq, J = 13.7 & 4.6 Hz, CHCH3), 1.91 (3H, s, CH3), 1.62-1.59 (1H, m, CH), 1.17 
(6H, d, J = 6.3 Hz, CH(CH3)2), 1.08 (3H, d, J = 4.6 Hz, CHCH3); 13C NMR (CDCl3, 
150 MHz, ppm) δC 210.4 (s), 173.0 (s), 155.3 (s), 133.4 (s), 67.5 (d), 40.9 (d), 33.8 (t), 
32.1 (t), 30.2 (t), 21.9 (2 × q), 21.5 (t), 15.3 (q); LRMS (CI) m/z 240 (7%), 239 (48), 
197 (14), 179 (100), 150 (5); HRMS (CI) C14H23O3 [M+H] requires 239.16472, found 
239.16461. 
 
6-hydroxyl-1,6-dimethylbicyclo[3.3.1]nonane-2,9-dione 105 
 
 
 
Dimethylhydrazine dihydrochloride (0.013 g, 0.01 mmol) was added to a solution of 
triketone 39 (0.20 g, 1.02 mmol) in tert-butanol (2 mL) and stirred at 70 °C for 3 h.  
After removal of the solvent in vacuo, the resulting residue was purified by column 
chromatography (10 ethyl acetate:dichloromethane) to afford the title compound (0.039 
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g, 22%) as a colourless oil; IR νmax/cm-1 (film) 3426.6, 2934.8, 1727.0, 1695.1; 1H 
NMR (CDCl3, 600 MHz, ppm) δH 2.66 (1H, dt, J = 9.0 & 2.1 Hz, CH), 2.56 (1H, ddd, J 
= 16.4, 7.2 & 6.1 Hz, CH), 2.41 (1H, t, J = 8.5 Hz, CH), 2.10-2.05 (1H, m, CH), 2.04 
(1H, dd, J = 4.0 & 1.0 Hz, CH), 2.02 (1H, dd, J = 4.0 & 1.0 Hz, CH), 1.93 (1H, bs, 
OH), 1.79 – 1.73 (2H, m, CH2), 1.64 (1H, dt, J = 14.6 & 4.3 Hz), 1.37 (3H, s, CH3), 
1.16 (3H, s, CH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 211.7 (s), 79.1 (s), 62.6 (s), 
57.1 (d), 38.5 (t), 37.2 (t), 32.5 (t), 28.1 (q), 19.4 (t), 16.6 (q); LCMS (CI) m/z 240 (13), 
239 (60), 238 (3), 197 (24), 180 (13), 179 (91), 178 (5), 150 (6); HRMS (CI) C14H23O3 
[M+H] requires 239.16472, found 239.16491. 
 
6-hydroxyl-1,6-dimethylbicyclo[3.3.1]nonane-2,9-dione 105 
 
 
 
Triketone 39 (0.20 g, 1.02 mmol) was combined with dimethylhydrazine 
dihydrochloride (0.013 g, 0.01 mmol) and stirred at room temperature for 7 days.  The 
residue was purified by column chromatography (20-40% ethyl acetate:petroleum ether) 
to afford the title compound (0.10 g, 56%) as a colourless oil; IR νmax/cm-1 (film) 
3426.6, 2934.8, 1727.0, 1695.1; 1H NMR (CDCl3, 600 MHz, ppm) δH 2.66 (1H, dt, J = 
8.9 & 2.0 Hz, CH), 2.55 (1H, ddd, J = 16.6, 7.6 & 6.2 Hz, CH), 2.42 – 2.35 (1H, m, 
CH), 2.09-2.01 (4H, m), 1.79 – 1.73 (2H, m, CH2), 1.67-1.62 (1H, m, CH), 1.37 (3H, s, 
CH3), 1.15 (3H, s, CH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 210.2 (s), 80.3 (s), 61.8 
(s), 57.4 (d), 39.1 (t), 36.0 (t), 32.4 (t), 28.9 (q), 19.9 (t), 15.9 (q); LCMS (CI) m/z 240 
(10), 239 (52), 197 (18), 180 (15), 179 (100); HRMS (CI) C14H23O3 [M+H] requires 
239.16472, found 239.16461. 
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Methyl-2-(prop-2-yn-1-yloxy)acetate 120 
 
 
 
To a stirring suspension of potassium tert-butoxide (16.01 g, 142.7 mmol) in anhydrous 
tetrahydrofuran (200 mL) at 0 °C, propargyl alcohol (4.15 mL, 71.4 mL) was added 
dropwise followed by the dropwise addition of methyl bromoacetate (8.14 mL, 85.6 
mmol) and the resulting solution was stirred for 3.5 h at room temperature.  After 
quenching the reaction with distilled water (60 mL), the solution was diluted with 
dichloromethane (50 mL) and the aqueous layer extracted with dichloromethane (3 x 40 
mL).  The combined organic layers were washed with brine (50 mL) and dried, filter 
and concentrated in vacuo to afford the crude product, which was purified via column 
chromatography (10% ethyl acetate: petroleum ether) to afford the title compound (3.38 
g, 37%) as a colourless oil; IR νmax/cm-1 (film) 3291, 2883, 2241, 1745, 1386, 1143; 1H 
NMR (CDCl3, 400 MHz, ppm) δH 4.21 (2H, d, J = 3.65 Hz, CH2), 4.10 (2H, s, CH2), 
3.66 (3H, s, CH3), 2.44 (1H, t, J = 2.4 Hz, CH); 13C NMR (CDCl3, 125 MHz, ppm) δC 
170.3 (s), 78.4 (s), 66.8 (q), 58.5 (d), 52.1 (t), 14.0 (d); LCMS (CI) m/z 129 (100%), 121 
(8), 115 (8), 107 (23), 101 (60), 91 (20); HRMS (CI) C6H9O3 [M+] requires 129.05517, 
found 129.05538. Data consistent with literature values.44  
 
Methyl 2-(2-oxopropoxy)acetate 113 41 
 
 
 
To a stirring solution of alkyne 120 (3.38 g, 26.4 mmol), and methanol (80 mL), 
mercury(II) acetate (0.68 g, 2.64 mmol) and concentrated sulfuric acid (0.05 mL) was 
added and the solution heated to reflux for 20 min.  After cooling, the solvent was 
removed in vacuo and dichloromethane (30 mL) was added to the resulting residue.  
After addition of 1M HCl (30 mL), the aqueous layer was extracted with 
dichloromethane (3 x 20 mL) and the combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo to afford the crude product. Purification via column 
chromatography (40% ethyl acetate: petroleum ether) afforded the title compound (0.68 
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g, 18%) as a yellow oil; IR νmax/cm-1 (film) 3537.3, 2956.9, 2921.8, 1730.7, 1437.8, 
1358.5; 1H NMR (CDCl3, 400 MHz, ppm) δH 4.21 (2H, s, CH2O), 4.20 (2H, s, OCH2), 
3.76 (3H, s, OCH3), 2.18 (3H, s, CH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 205.6 (s), 
170.4 (s), 74.4 (t), 67.8 (t), 51.8 (q), 25.1 (q); LCMS (CI) m/z 129 (95%), 121 (7), 115 
(5), 111 (15), 107 (20), 101 (55), 91 (20): HRMS (CI) C6H10O4 [M+H]+ requires 
147.06573, found 147.06573. Data consistent with literature values.41  
 
2-((2-methylallyl)oxy)acetic acid 129 
 
 
 
To a suspension of sodium hydride (2.50 g, 105.8 mmol) in anhydrous 
dimethylformamide (10 mL) at 0 °C, methallyl alcohol was added dropwise and stirred 
for 30 mins.  A solution of chloroacetic acid (5.00 g, 52.90 mmol) in anhydrous 
dimethylformamide (10 mL) was added dropwise and warmed to room temperature and 
stirred until complete by TLC.  The reaction was quenched by the dropwise addition of 
water (10 mL) and 2M HCl(aq) (10 mL) and extracted with ethyl acetate (3 x 15 mL).  
The combined organic layers were washed with saturated LiCl solution (2 x 30 mL), 
followed by brine (20 mL) and dried, filtered and concentrated in vacuo to afford the 
title compound (6.50 g, 94%) as a yellow oil; IR νmax/cm-1 (film) 2922.8, 1725.8; 1H 
NMR (CDCl3, 400 MHz, ppm) δH 11.35 (1H, s, OH), 5.00 (1H, s, C=CHH), 4.98 (1H, 
s, C=CHH), 4.10 (2H, s, CH2O), 4.03 (2H, s, OCH2), 1.77 (3H, s, CH3); 13C NMR 
(CDCl3, 100 MHz, ppm) δC 182. 9 (s), 140.7 (s), 113.9 (t), 66.3 (t), 40.5(t), 19.3 (q); 
LCMS (EI) 130 (7%), 86 (58), 84 (100), 71 (57), 60 (79), 57 (23), 55 (53). Data 
consistent with literature values.207  
 
Methyl 2-((2-methylallyl)oxy)acetate 13041  
 
 
 
Amberlyst-15 ion-exchange resin (0.50 g) was added to a stirring solution of 2-((2-
methylallyl)oxy)acetic acid 129 (15.9 g, 112.7 mmol) in methanol (200 mL) and heated 
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to 60 °C.  After 16 h, the reaction mixture was cooled to room temperature and filtered.  
The resulting solution was concentrated in vacuo to afford the title compound (9.66 g, 
55 %) as a pale yellow oil; IR νmax/cm-1 (film) 2953.2, 1756.1, 1656.7, 1438.2, 1376.5; 
1H NMR (CDCl3, 400 MHz, ppm) δH 4.99 (1H, s, C=CHH), 4.94 (1H, s, C=HH), 4.02 
(2H, s, CH2), 3.82 (2H, s, CH2), 3.78 (3H, s, OCH3), 1.77 (3H, s, CH3); 13C NMR 
(CDCl3, 100 MHz, ppm) δC 171.0 (s), 141.1 (s), 113.4 (t), 75.9 (t), 67.3 (t), 55.1 (q), 
19.3 (q); LCMS (CI) m/z 145 (100%), 131 (19), 113 (8), 109 (14), 103 (46), 91 (22), 85 
(40), 74 (9); HRMS (CI) C7H13O2 [M+H]+ requires 145.08647, found 145.08587. 
 
Methyl 2-(2-oxopropoxy)acetate 11341  
 
 
 
To a stirring solution of methyl 2-((2-methallyloxy)acetate 130 (9.66 g, 67.1 mmol) in 
tetrahydrofuran (10 mL), osmium tetroxide –polymer bound fibrecat (0.17 g, 0.67 
mmol) in distilled water (5 mL) and tetrahydrofuran (50 mL) was added followed by the 
dropwise addition of a solution of sodium periodate (28.7 g, 134.2 mmol) in distilled 
water (200 mL).  The resulting reaction mixture was stirred at room temperature for 16 
h.  The colourless heterogenous reaction mixture was filtered and the filter cake washed 
with water (100 mL).  The filtrate was washed with tert-butyl methyl ether (150 mL) 
and the aqueous layers were extracted with dichloromethane (4 x 200 mL).  The 
combined organic layers were dried with Na2SO4, filtered and concentrated in vacuo to 
afford the title compound (3.66 g, 42 %) as a yellow oil; IR νmax/cm-1 (film) 3537.3, 
2956.9, 2921.8, 1730.7, 1437.8, 1358.5; 1H NMR (CDCl3, 400 MHz, ppm) δH 4.21 (2H, 
s, CH2O), 4.20 (2H, s, OCH2), 3.76 (3H, s, OCH3), 2.18 (3H, s, CH3); 13C NMR 
(CDCl3, 150 MHz, ppm) δC 205.6 (s), 170.4 (s), 74.4 (t), 67.8 (t), 51.8 (q), 25.1 (q); 
LCMS (CI) m/z 129 (95%), 121 (7), 115 (5), 111 (15), 107 (20), 101 (55), 91 (20): 
HRMS (CI) C6H10O4 [M+H]+ requires 147.06573, found 147.06573. Data consistent 
with literature values.41  
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Pyran-3,5-dione 7441  
 
 
 
To a three-necked flask containing refluxing anhydrous tetrahydrofuran (20 mL), a 
solution of methyl 2-(2-oxopropoxy)acetate 113 (23.19 g, 159 mmol) in anhydrous 
tetrahydrofuran (250 mL) and a solution of potassium tert-butoxide (21.37 g, 190 
mmol) in anhydrous tetrahydrofuran (250 mL) were added in a simultaneous dropwise 
manner.  Once the addition was complete, the reaction mixture was stirred at reflux for 
a further 5 mins before quenching with the dropwise addition of distilled water (10 mL).  
After cooling to room temperature, the pH of the resulting brown solution was adjusted 
to 1 using aqueous 2M HCl solution and the aqueous layer was extracted with ethyl 
acetate (3 x 200 mL).  The combined organic layers were dried with MgSO4, filtered 
and concentrated in vacuo to afford the title compound (16.55 g, 91 %) as a viscous 
brown oil; IR νmax/cm-1 (film) 2484.81, 1641.99, 1538.51; 1H NMR (DMSO-d6, 400 
MHz, ppm) δH 11.8 (1H, s, OH), 5.31 (1H, s, C=CH), 4.08 (4H, s, 2x CH2), 3.32 (2H, s, 
CH2); LCMS m/z (ES+) 114.9 (100%). Data consistent with literature values.41  
 
2-((3-methoxybenzyl)oxy)acetic acid 16797 
 
 
 
To a suspension of sodium hydride (6.09 g, 253 mmol) in anhydrous DMF (20 mL), 3-
methoxybenzyl alcohol 142 (9.47 mL, 76.2 mmol) was added dropwise at 0 °C.  After 
stirring for 1 h at 0 °C, a solution of chloroacetic acid (6.00 g, 63.5 mmol) in anhydrous 
DMF (10 mL) was added dropwise and after stirring at room temperature for 18 h, the 
reaction mixture was cooled to 0 °C and quenched with the dropwise addition of water 
(30 mL).  The pH of the reaction mixture was adjusted to 10 with concentrated NaOH 
aqueous solution and washed with diethyl ether (40 mL). The pH of the aqueous layer 
was adjusted to 2 using concentration HCl aqueous solution and extracted with diethyl 
ether (3 x 30 mL).  The combined organic layers were washed with saturated LiCl 
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solution (2 x 30 mL), followed by brine (30 mL) and dried (MgSO4), filtered and 
concentrated in vacuo to afford the title compound (9.79 g, 96 %) as colourless oil; IR 
νmax/cm-1 (film) 2939.1, 1730.0, 1587.5, 1266.9; 1H NMR (CDCl3, 400 MHz, ppm) δH 
7.30 (1H, t, J = 8.33 Hz, ArH), 6.97 – 6.93 (2H, m, ArH), 6.89 (1H, dd, J = 8.33 & 2.49 
Hz, ArH), 4.65 (2H, s, CH2), 4.16 (2H, s, CH2), 3.84 (3H, s, OCH3); 13C NMR (CDCl3, 
150 MHz, ppm) δC 177.4 (s), 159.9 (s), 138.2 (s), 129.8 (d), 120.4 (d), 114.0 (d), 113.4 
(d), 73.4 (t), 66.7 (t), 55.3 (q); LRMS (EI)  262 (25%), 178 (10), 149 (13), 148 (20), 137 
(24), 121 (75), 109 (63), 98 (25), 97 (45), 95 (75); HRMS (EI) C10H12O4 [M+] requires 
196.07301, found 196.07261. Data consistent with literature values.98  
 
7-Methoxyisochroman-4-one 14597  
 
 
 
A solution of 2-((3-methoxybenzyl)oxy)acetic acid 167 (4.72 g, 24.1 mmol) in 
dichloromethane (50 mL) was cooled to 0 °C under argon and oxalyl chloride (4.21 mL, 
48.2 mmol) and DMF (0.1 mL) were added dropwise.  After stirring at 50 °C for 18 h, 
the reaction mixture was cooled to 0 °C and following the dropwise addition of tin (VI) 
chloride (1M in dichloromethane, 10.5 mL) allowed to stir for 1 h.  Saturated NaHCO3 
solution (30 mL) and water (30 mL) were added to the reaction mixture and the 
resulting solution was extracted with dichloromethane (3 x 30 mL).  The combined 
organic layers were washed with brine and dried (MgSO4), filtered and concentrated in 
vacuo. The resulting crude oil was purified by column chromatography (10-20 % ethyl 
acetate: petroleum ether) to afford the title compound (2.12 g, 50 %) as a white solid; 
m.p. 76-79 °C (lit.98 value 78-80 °C); IR νmax/cm-1 (film) 2969.3, 2845.5, 2809.5, 
1672.9 1595.5, 1572.8; 1H NMR (CDCl3, 600 MHz, ppm) δH 8.02 (1H, d, J = 8.58 Hz, 
ArH), 6.91 (1H, dd, J = 8.58 & 2.50 Hz, ArH), 6.66 (1H, d, J = 2.50 Hz, ArH), 4.85 
(2H, s, CH2), 4.33 (2H, s, CH2), 3.88 (3H, s, OCH3); 13C NMR (CDCl3, 150 MHz, ppm) 
δC 193.0 (s), 169.2 (s), 164.3 (s), 129.2 (s), 123.2 (s), 114.3 (d), 108.9 (d), 73.5 (t), 68.2 
(t), 55.3 (q); LRMS (EI) 149 (8%), 148 (100), 120 (28), 105 (10); HRMS (EI) C10H10O3 
[M+] requires 178.06245, found 178.06208. Data consistant with literature values.97  
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2-Chloro-N, N-dimethylacetamide 173208 
 
 
 
A solution of chloroacetyl chloride 172 (3.52 mL, 45.0 mmol) in anhydrous THF (20 
mL) was cooled to -20 °C and dimethylamine (2M in THF, 27 mL) was added 
dropwise.  After stirring at room temperature for 18 h, the reaction mixture was cooled 
to 0 °C and quenched with 2M HCl(aq) (20 mL).  The resulting mixture was extracted 
with dichloromethane (3 x 15 mL) and the combined organic layers were washed with 
brine (15 mL) before being dried (Na2SO4), filtered and concentrated in vacuo to afford 
a yellow oil.  Purification was achieved via column chromatography (15% diethyl ether: 
petroleum ether) to afford the title compound (2.75 g, 50 %) as a colourless oil; IR 
νmax/cm-1 (film) 2936.8, 1650.4; 1H NMR (CDCl3, 500 MHz, ppm) δH 4.12 (2H, s, 
CH2), 3.12 (3H, s, NCH3), 3.01 (3H, s, NCH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 
168.9 (s), 41.2 (t), 37.8 (q), 36.1 (q). Data consistent with literature values.208  
 
2-(3-methoxybenzyoxy)-N, N-dimethylacetamide 174 
 
 
 
To a suspension of sodium hydride (1.32 g, 55.1 mmol) in anhydrous DMF (20 mL), 3-
methoxybenzyl alcohol (2.73 mL, 22.02 mmol) was added dropwise at 0 ºC. After 
stirring at room temperature for 30 mins, the reaction mixture was cooled to 0 ºC and a 
solution of 2-chloro-N,N-dimethylacetamide 173 (2.22 g, 18.4 mmol) in anhydrous 
DMF (10 mL) was added dropwise. After stirring for 3 h, the reaction was quenched 
with the dropwise addition of water (5 mL) and partitioned between dichloromethane 
(20 mL) and water (15 mL).  The aqueous layer was extracted with dichloromethane (2 
x 15 mL) and the combined organic layers were washed with 2M hydrochloric acid 
solution (10 mL) and saturated lithium chloride solution (2 x 20 mL).  The 
dichloromethane layers were dried with Na2SO4, filtered and concentrated in vacuo to 
afford the crude product, which was purified by column chromatography (80% diethyl 
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ether: petroleum ether) to afford the title compound (1.97 g, 48%) as a yellow oil; IR 
νmax/cm-1 (film) 3055.4, 2932.0, 1713.2, 1646.8 1602.4, 1585.8; 1H NMR (CDCl3, 400 
MHz, ppm) δH 7.27 (1H, t, J = 7.88 Hz, ArH), 6.96 – 6.93 (2H, m, ArH), 6.85 (1H, d, J 
= 7.88 Hz, ArH), 4.61 (2H, s, OCH2C=O), 4.19 (2H, s, ArCH2O), 3.82 (3H, s, OCH3), 
2.99 (3H, s, NCH3), 2.97 (3H, s, NCH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 169.4 
(s), 159.8 (s), 138.1 (s), 129.6 (d), 120.3 (d), 113.1 (d), 113.3 (d), 73.3 (t), 69.1 (t), 55.4 
(q), 36.5 (q), 35.7 (q); LCMS (CI) m/z 170 (18%), 169 (9), 163 (3), 157 (15), 147 (10), 
146 (51), 144 (80), 131 (14), 121 (3), 116 (18), 104 (20), 86 (71), 84 (68), 77 (25), 51 
(50). 
 
7-Methoxyisochroman-4-one 14597 
 
 
 
To a stirring solution of amide 179 (0.30 g, 1.35 mmol) in dichloroethane (2 mL), triflic 
anhydride (0.27 mL, 1.61 mmol) was added in a single portion and heated to 40 °C.  
After 3 h, the reaction mixture was poured into a 50:50 mixture of diethyl ether and 1M 
K2CO3 (aq) (6 mL) and stirred for 1 h.  The phases were separated and the aqueous layer 
extracted with diethyl ether (2 x 5 mL).  The combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo to afford the crude product.  Purification 
via column chromatography (25 % diethyl ether: petroleum ether) afforded the title 
compound (0.039 g, 17 %) as a white solid m.p. 80-81 °C (lit.98 value 78-80 °C); IR 
νmax/cm-1 (film) 2969.3, 2845.5, 2809.5, 1672.9 1595.5, 1572.8; 1H NMR (CDCl3, 600 
MHz, ppm) δH 8.02 (1H, d, J = 8.58 Hz, ArH), 6.91 (1H, dd, J = 8.58 & 2.50 Hz, ArH), 
6.66 (1H, d, J = 2.50 Hz, ArH), 4.85 (2H, s, CH2), 4.33 (2H, s, CH2), 3.88 (3H, s, 
OCH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 193.0 (s), 169.2 (s), 164.3 (s), 129.2 (d), 
123.2 (d), 114.3 (d), 108.9 (d), 73.5 (t), 68.2 (t), 55.3 (q); LRMS (EI) 149 (8%), 148 
(100), 120 (28), 105 (10); HRMS (EI) C10H10O3 [M+] requires 178.06245, found 
178.06208. Data consistent with literature values.97  
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2-((3-methoxybenzyl)oxy)acetonitrile 179 
 
 
 
3-Methoxylbenzyl alcohol 142 (0.9 mL, 7.25 mmol) was added dropwise to a 
suspension of sodium hydride (0.35 g, 14.5 mmol) in anhydrous THF (20 mL) at 0 °C 
and stirred at room temperature for 1 h.  After cooling to 0 °C, bromoacetonitrile (0.59 
mL, 8.69 mmol) was added to the solution dropwise and stirred at room temperature for 
72 h.  After the dropwise addition of water (15 mL), the reaction mixture was washed 
with 2M HCl(aq) (15 mL) and extracted with dichloromethane (3 x 15 mL).  The 
combined organic layers were washed with saturated LiCl solution (2 x 20 mL), 
followed by brine (15 mL) and dried (Na2SO4), filtered and concentrated in vacuo to 
afford a brown oil.  Purification was achieved by column chromatography (80% 
dichloromethane: petroleum ether) to afford the title compound (0.22 g, 17 %) as a 
colourless oil; 1H NMR δH (CDCl3, 600 MHz, ppm) 7.28 (1H, t, J = 7.58 Hz, ArH), 
6.95 – 6.93 (2H, m, ArH), 6.84 (1H, dd, J = 7.58 & 2.39 Hz, ArH), 4.68 (2H, s, CH2), 
4.25 (2H, s, CH2), 3.82 (3H, s, OCH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 160.0, 
137.0, 129.9, 120.7, 114.4, 113.9, 73.1, 55.4, 54.9; LRMS (EI) m/z 167 (8%), 138 (30), 
135 (10), 122 (45), 121 (32), 120 (6), 109 (20), 107 (15), 85 (65), 83 (100); HRMS (EI) 
C10H11NO2 [M+] requires 177.07843, found 177.07814.  
 
7-Methoxy-3,4,5,8-tetrahydro-1H-isochromen-4-ol 18397 
 
 
 
To a suspension of 145 (5.00 g, 28.1 mmol) in liquid ammonia (150 mL), anhydrous 
diethyl ether (24 mL) and ethanol (42.5 mL), sodium metal (4.80 g, 210.7 mmol) was 
added in portions at a rate to maintain the deep blue colour noted after a third of the 
sodium had been added.  After allowing the ammonia to evaporate, the residue was 
partitioned between water (100 mL) and diethyl ether (20 mL).  The organic layer was 
separated and the aqueous layer was extracted with diethyl ether (2 x 30 mL).  The 
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combined organic layers were washed with brine and dried (MgSO4), filtered and 
concentrated in vacuo.  The resulting crude solid was purified by column 
chromatography (25 – 75 % diethyl ether: petroleum ether) to afford the title compound 
(2.05 g, 40 %) as a colourless solid; m.p 101-103 °C; IR νmax/cm-1 (film) 3423.6, 
2952.9, 2938.8, 2832.5, 1668.8; 1H NMR (CDCl3, 600 MHz, ppm) δH 4.71 (1H, t, J = 
3.3 Hz, C=CH), 3.96 (2H, d, J = 2.2 Hz, CH2) 3.70 (2H, dt, J = 10.8 & 2.2 Hz, CH2), 
3.57 (3H, s, OCH3) 3.18 (1H, dtt, J = 21.2, 7.4 & 3.3 Hz, CHH), 2.69 (1H, d, J = 21.2 
Hz, C=CHCHH), 2.55 (2H, t, J = 7.44 Hz, CH2), 2.35 (1H, s, OH) 1.82 (1H, d, J = 10.8 
Hz, CH); 13C NMR (CDCl3, 150 MHz, ppm) δC 151.6 (s), 128.2 (s), 126.7 (s), 90.7 (d), 
71.6 (t), 68.1 (t), 65.9 (d), 54.1 (q), 29.0 (t), 28.5 (t); LRMS (EI) 180 (5%) 164 (18) 150 
(15) 149 (23) 137 (45) 134 (100) 128 (20) 123 (23) 122 (25) 121 (50) 109 (40) 107 (20) 
91 (50); HRMS (EI) C10H14O3 [M+] requires 182.09375 found 182.09410. 
 
7-Methoxy-5,8-dihydro-1H-isochromen-4(3H)-one 14697 
 
 
 
To a solution of alcohol 183 (1.38 g, 7.58 mmol) in dry toluene (14 mL) and acetone (7 
mL), aluminium isopropoxide (0.77 g, 3.79 mmol) was added and stirred at reflux for 6 
h.  After cooling to room temperature, the reaction mixture was poured into brine (15 
mL) and filtered through celite.  The filter cake was washed with ether (2 x 20 mL) and 
the aqueous layer was extracted with ether (2 x 20 mL).  The combined organic layers 
were concentrated in vacuo and the crude solid was recrystalised from hot methanol to 
afford the title compound (0.79 g, 58 %) as a white crystalline solid; m.p 114-117 °C; 
1H NMR (CDCl3, 600 MHz, ppm) δH 4.74 (1H, t, J = 3.5 Hz, CH=C), 2.27 (2H, s, 
C(O)CH2) 4.18 (2H, s, OCH2) 3.57 (3H, s, OCH3) 3.03-2.98 (2H, m, C=CHCH2) 2.84 
(2H, t, J = 7.3 Hz, MeOCCH2); 13C NMR (CDCl3, 150 MHz, ppm) δC 193.5 (s), 150.9 
(s), 149.9 (s), 128.4 (s), 90.69 (d), 73.5 (t), 67.8 (t), 54.3 (q), 30.1 (t), 22.8 (t); LRMS 
(CI) m/z 181 (20%), 180 (7), 166 (12), 165 (100), 163 (28), 147 (10), 135 (13), 121 
(18), 105 (4); HRMS (CI) C10H13O3 [M+] requires 181.09647 found 181.08689. 
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7-Methoxy-4a-methyl,5-dihydro-1H-isochromen-4(3H)-one 144 
 
 
 
Potassium hexamethyldisilazane (0.5M in toluene, 1.54 mL, 0.77 mmol) was added 
dropwise to a solution of enone 146 (0.14 g, 0.77 mmol) in THF (2 mL), cooled to -78 
°C and left to stir for 10 min.  Methyl iodide (0.096 mL, 1.55 mmol) was added to the 
reaction mixture.  After stirring for 30 min, the reaction mixture was warmed to room 
temperature and partitioned between water (10 mL) and diethyl ether (10 mL).  The 
aqueous layer was extracted with diethyl ether (3 x 10 mL) and the combined organic 
layers were washed with brine (30 mL), dried (MgSO4), filtered and concentrated in 
vacuo to afford the crude product.  Purification was achieved via column 
chromatography (5% diethyl ether: petroleum ether) to yield the title compound (0.02 g, 
13%) as a colourless oil; 1H NMR (CDCl3, 600 MHz, ppm) δH 5.63 (1H, d, J = 1.9 Hz, 
C=CH), 4.60 (1H, dt, J = 6.9 & 2.0 Hz, CH2C=CH), 4.62 (1H, d, J = 14.7 Hz, OCH2), 
4.29 (1H, d, J = 14.7 Hz, CH2), 4.25 (1H, d, J =17.1 Hz, CH2), 4.05 (1H, d, J = 17.1 Hz, 
OCH2), 3.54 (3H, s, OCH3), 2.54 (1H, d, J = 17.0 Hz, CH2), 2.36 (1H, dd, J = 17.0 & 
6.9 Hz, CH2), 1.37 (3H, s, CH3); 13C NMR (CDCl3, 125 MHz, ppm) δC 211.4 (s), 151.9 
(s), 139.5 (s), 118.4 (d), 89. 7 (d), 73. 4 (t), 68.9 (t), 54.7 (q), 46.5 (s), 29.9 (t), 22.4 (q).  
 
1-Bromo-N,N-diethyl-2-phenylethenesulfonamide 391 
 
 
 
To a stirring solution of trans-β-styrenesulfonyl chloride (3.00 g, 14.8 mmol) in 
dichloromethane (30 mL), a solution of amine (3.09 mL, 29.6 mmol) in 
dichloromethane (40 mL) was added dropwise over 15 mins at −78 °C.  Upon 
completion of the addition, the reaction mixture was warmed to room temperature and 
diluted with dichloromethane (50 mL), followed by washing with 2 M HCl aqueous 
solution (50 mL) and brine (50 mL).  The organic layer was dried (MgSO4), filtered and 
the volume of organic solvent reduced to half the original volume. Bromine (1.89 mL, 
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37.0 mmol) was added to the stirring crude ethylsulfonamide dichloromethane solution 
and stirred at room temperature for 1 h, until complete consumption of the starting 
material was observed by TLC.  After cooling to 0 °C, an aqueous solution of 1M 
sodium thiosulfate (20 mL) added dropwise to the reaction mixture and stirred until the 
red-brown colour turned yellow.  The aqueous phase was separated and extracted with 
dichloromethane (2 x 20 mL).  The combined organic phases were washed with brine 
(20 mL) and dried (MgSO4), filtered and the volume reduced by half in vacuo. The 
resulting solution was cooled to 0 °C and triethylamine (1.89 mL, 13.6 mmol) was 
added dropwise.  After stirring until complete consumption of the dibromo-intermediate 
by TLC (1 h), the reaction mixture was diluted with dichloromethane (50 mL) and 
washed with 2M hydrochloric aqueous solution (30 mL) and brine (30 mL).  The 
organic layer was dried (MgSO4), filtered and concentrated in vacuo to afford the crude 
product. Purification was achieved via column chromatography (0-20% diethyl 
ether:petroleum ether) to afford the title compound (2.19 g, 57%) as a colourless oil; IR 
νmax/cm-1 (film) 3059, 2935, 2870, 1695, 1496, 1435, 1389, 1258; 1H NMR (CDCl3, 
600 MHz, ppm) δH 8.04 (1H, s, CH=C), 7.77-7.75 (2H, m, ArH), 7.45-7.43 (3H, m, 
ArH), 3.42 (4H, q, J = 7.2 Hz, NCH2CH3), 1.24 (6H, t, J = 7.2 Hz, NCH2CH3); 13C 
NMR (CDCl3, 125 MHz, ppm) δC 137.7 (d), 132.5 (d), 130.5 (d), 129.9 (d), 128.7 (s), 
119.9 (s), 43.1 (t), 14.5 (q); LRMS (CI) 240 (100%), 224 (15), 167 (10), 103 (5), 71 (5); 
HRMS (CI) calc’d for C12H18NO2S [M +H]+ requires 240.10582, found 240.10518. 
 
N,N-diethyl-2-phenylethynesulfonamide 197 
 
 
 
Vinylbromosulfonamide 391 (2.18 g, 6.85 mmol) in dimethylformamide (5 mL) was 
added dropwise to a stirring solution of sodium hydride (0.33 g, 13.7 mmol) in 
dimethylformamide (20 mL) at 0 °C.  After complete consumption of the starting 
material was observed via TLC, the reaction mixture was quenched with the dropwise 
addition of water (5 mL) at 0 °C.  After dilution with water (30 mL), the aqueous layer 
was extracted with diethyl ether (3 x 30 mL) and the combined organic layers were 
washed with saturated lithium chloride aqueous solution (2 x 20 mL) and brine (20 
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mL). The organic layers were dried (MgSO4), filtered and concentrated in vacuo to 
afford the crude product, which was purified by column chromatography (10% diethyl 
ether: petroleum ether) to give the title compound as colourless oil (0.88 g, 55%); IR 
νmax/cm-1 2978, 2181, 1737, 1357, 1152, 1016; 1H NMR (CDCl3, 600 MHz, ppm) δH 
7.54 (2H, d, J = 7.58 Hz, oArH), 7.47 (1H, t, J = 7.6 Hz, pArH), 7.39 (2H, t, J = 7.6 Hz, 
mArH), 3.39 (4H, q, J = 7.2 Hz, NCH2CH3), 1.29 (6H, t, J = 7.2 Hz, NCH2CH3); 13C 
NMR (CDCl3, 150 MHz, ppm) δC 132.8 (d), 131.1 (d), 128.8 (d), 118.7 (s), 88.3 (s), 
83.9 (s), 43.0 (t), 13.5 (q); LRMS (CI) m/z 238 (29%), 222 (100), 173 (60), 165 (50), 
158 (10), 130 (4), 115 (18), 102 (14), 89 (19), 84 (9), 71 (5); HRMS (CI) calc’d for 
C12H15NO2S [M+H]+ requires 238.08963, found 238.08902. Data consistent with 
literature values.137  
 
General procedures for the synthesis of α-aminosulfonamides 
 
Procedure A 
To a flame-dried three-necked flask containing an atmosphere of argon, potassium 
hydride (0.4 mmol) was added to anhydrous THF (1 mL) in one portion and the stirring 
suspension was cooled to 0 ºC. Amine (0.4 mmol) was added to the reaction suspension 
dropwise and stirred at room temperature for 30 mins.  After cooling to room 
temperature, dimethylamine (2.0 M in THF, 0.2 mmol) was added and allowed to stir 
for 10 mins.  Alkynylsulfonamide (0.1 mmol) was added to the reaction mixture in one 
portion and stirred at 0 ºC for 15 mins.  The reaction mixture was quenched with the 
dropwise addition of iso-propanol (0.5 mL), followed by partitioning between water (2 
mL) and dichloromethane (2 mL).  The aqueous layer was extracted with 
dichloromethane (2 x 3 mL). The combined organic layers were washed with brine (4 
mL) and dried (MgSO4), filtered and concentrated in vacuo to afford the crude product, 
which was purified by column chromatography. 
 
Procedure B 
To a flame-dried three-necked flask equipped with an argon balloon and a reflux 
condenser, freshly cut potassium metal (0.4 mmol) was added to the amine (0.4 mmol) 
and heated until all the potassium had been dispersed.  After cooling the salt to 0 ºC, 
dimethylamine (2.0 M in THF, 0.2 mmol) was added and stirred for 10 mins.  
Alkynylsulfonamide (0.1 mmol) was added in one portion and stirred at 0ºC for 15 
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mins.  The reaction mixture was quenched with the dropwise addition of iso-propanol 
(0.5 mL), followed by partitioning between water (2 mL) and dichloromethane (2 mL).  
The aqueous layer was extracted with dichloromethane (2 x 3 mL). The combined 
organic layers were washed with brine (4 mL) and dried (MgSO4), filtered and 
concentrated in vacuo to afford the crude product, which was purified by column 
chromatography. 
 
(E)-N,N-diethyl-1-(methyl(phenyl)amino)-2-phenylethenesulfonamide 368 
 
 
 
Procedure A. N-methylaniline. Colourless oil (31 mg, 52%); IR νmax/cm-1 (film) 3054.4, 
1448.6, 1318.0,1199.4, 931.2, 749.1 1H NMR (CDCl3, 600 MHz, ppm) δH 7.66 (1H, s, 
C=CH), 7.47 (2H, d, J= 7.0 Hz, oArH), 7.33-7.27 (3H, m, ArH), 7.22 (2H, t, J = 7.5 Hz, 
NArH), 6.81 (1H, t, J = 7.5 Hz, NArH), 6.77 (2H, d, J = 7.5 Hz, NArH), 3.25 (3H, s, 
NCH3), 2.98-2.91 (4H, m, N(CH2CH3)2), 1.91 (6H, t, J = 7.2 Hz, N(CH2CH3)2); 13C 
NMR (CDCl3, 150 MHz, ppm) δC 145.3 (s), 140.6 (s), 136.0 (d), 131.9 (s), 130.5 (d), 
130.0 (d), 129.4 (d), 129.1 (d), 119.2 (d), 113.7 (d), 43.5 (t), 38.9 (q), 16.1 (q); LRMS 
(CI) 344 (12%) 236 (6), 229 (11), 208 (100), 185 (9), 84 (26); HRMS (CI) 
C19H24N2O2S [M+] requires 344.15585, found 344.15549. 
 
 (E)-1-(benzyl(phenyl)amino)-N,N-diethyl-2-phenylethenesulfonamide 374 
 
 
 
Procedure A. N-benzylaniline. Colourless oil (31 mg, 52%); IR νmax/cm-1 (film) 3359.3, 
1596.1, 1494.5 1264.7, 906.5 726.5; 1H NMR (CDCl3, 600 MHz, ppm) δH 7.66 (1H, s, 
C=CH), 7.44 (2H, d, J = 7.64 Hz, ArH), 7.32 – 7.29 (2H, m, ArH), 7.25-7.21 (6H, m, 
ArH), 7.11-7.08 (3H, m, ArH), 6.92 (2H, d, J = 7.7 Hz, NArH), 6.84 (1H, t, J = 7.3 Hz, 
p-NArH) 4.83 (2H, s, CH2), 2.88 – 2.82 (4H, m, N(CH2CH3)2), 1.07 (6H, t, J = 7.1 Hz, 
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N(CH2CH3)2); 13C NMR (CDCl3, 150 MHz, ppm) δC 145.5 (s), 140.4 (s), 137.6 (d), 
136.7 (s), 131.8 (s), 130.5 (d), 130.3 (d), 129.4 (d), 129.1 (d), 128.6 (d), 127.9 (d), 127.2 
(d), 119.9 (d), 115.5 (d), 56.4 (t), 42.7 (t), 16.0 (q); LRMS (CI) 421 (9%), 302 (35), 284 
(100), 181 (9), 91 (11); HRMS (CI) C26H29N2O2S [M+] requires 420.19972, found 
420.19811. 
 
(Z)-N,N-diethyl-2-(2-oxopyrrolidin-1-yl)-2-phenylethenesulfonamide 376 
 
 
 
Procedure B. 2-Pyrrolidone. Colourless oil (58 mg, 71%); IR νmax/cm-1 (film) 2936.2, 
1639.5, 1599.0, 1410.3, 1324.0, 1261.3, 1203.6; 1H NMR (CDCl3, 600 MHz, ppm) δH 
7.46-7.39 (5H, m, ArH), 6.54 (1H, s, C=CH), 3.62 (2H, t, J = 7.3 Hz, C(O)CH2), 3.36 
(4H, q, J = 7.2 Hz, N(CH2CH3)2), 2.59 (2H, t, J = 7.4 Hz, NCH2CH2), 2.21 (2H, quin, J 
= 7.4 Hz, NCH2CH2CH2), 1.22 (6H, t, J = 7.2 Hz, N(CH2CH3)2); 13C NMR (CDCl3, 150 
MHz, ppm) δC 175.94 (s), 144.56 (s), 134.2 (s), 130.9 (d), 129.2 (d), 126.9 (d), 123.5 
(d), 50.1 (t), 42.0 (t), 31.4 (t), 19.5 (t), 14.7 (q); LRMS (CI) 264 (15%), 250 (100), 219 
(35), 214 (27), 197 (14), 186 (58), 169 (22), 149 (15), 137 (33), 131 (40), 119 (15), 109 
(13), 97 (21), 83 (22), 57 (33); HRMS (CI) C16H23N2O3S [M+] requires 323.14239, 
found 323.14197. 
 
(Z)-N,N-diethyl-3,3-dimethyl-2-(2-oxopyrrolidin-1-yl)but-1-ene-1-sulfonamide 377 
 
 
 
Procedure A. 2-pyrrolidone. Colourless oil. (19 mg, 23%); 1H NMR (CHCl3, 600 MHz, 
ppm) δH 6.11 (1H, s, CH=C), 3.72 (1H, q, J = 8.2 Hz, C(O)CH2), 3.61-3.56 (1H, m, 
C(O)CH2), 3.32 (2H, quin, J = 7.1 Hz, N(CH2CH3)2), 3.25 (2H, quin, J = 7.1 Hz, 
N(CH2CH3)2), 2.52 – 2.34 (2H, m, NCH2CH2), 2.23 – 2.02 (2H, m, NCH2CH2) 1.18 
(6H, t, J = 7.1 Hz, N(CH2CH3)2), 1.17 (9H, s, 3 x CH3); 13C NMR (CHCl3, 150 MHz, 
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ppm) δC 176.4 (s), 157.3 (s), 135.8 (s), 123.2 (d), 52.5 (t), 41.6 (t), 39.8 (s), 31.2 (t), 
28.9 (q), 19.6 (t), 14.7 (q); LCMS (CI) 303 (8%), 301 (4), 230 (99), 166 (58); HRMS 
(CI) C14H27N2O3S [M+] requires 303.17369, found 303.17349. 
 
(Z)-N, N-diethyl-2-(methyl(phenyl)amino)-2-phenylethenesulfonamide 369 
 
 
 
To a stirring solution of N-methylaniline (0.03 mL, 0.27 mmol) in anhydrous 
tetrahydrofuran (5 mL) cooled to −78 °C, nButyl Lithium (2.5M in hexanes, 0.12 mL, 
0.30 mmol) was added dropwise and stirred for 10 mins.  A solution of 
alkynylsulfonamide 197 (0.07 g, 0.30 mmol) in anhydrous tetrahydrofuran (2 mL) was 
added dropwise and the resulting reaction mixture was stirred at −78 °C for 2 h and at 
room temperature for a further 30 min.  The solution was partitioned between water (10 
mL) and dichloromethane (10 mL) and the aqueous layer extracted with 
dichloromethane (2 x 10 mL).  The combined organic layers were washed with brine 
(10 mL), dried (MgSO4), filtered and concentrated in vacuo to afford the crude product, 
which was purified via column chromatography (10-30% diethyl ether:petroleum ether) 
to afford the title compound (0.017 g, 20%) as a colourless oil; IR νmax/cm-1 (film) 
3043.7, 1442.9, 1324.4,1183.5, 939.4, 751.2 1H NMR (CDCl3, 600 MHz, ppm) δH 7.34-
7.32 (2H, m, ArH), 7.34-7.27 (3H, m, ArH), 7.21 (2H, t, J = 7.7 Hz, ArH), 7.07 (1H, t, J 
= 7.7 Hz, ArH), 7.02 (2H, d, J = 8.3 Hz, ArH), 5.28 (1H, s, CH=C), 3.14 (3H, s, CH3), 
2.92 (4H, q, J = 7.4 Hz, N(CH2CH3)2), 1.03 (6H, t, J = 7.4 Hz, N(CH2CH3)2); 13C NMR 
(CDCl3, 150 MHz, ppm) δC 158.7 (s), 155.0 (s), 133.8 (s), 130.3 (d), 129.4 (d), 129.2 
(d), 127.7 (d), 126.2 (d), 100.6 (d), 41.8 (q), 41.4 (t), 14.3 (q); LRMS (CI) 344 (15%), 
236 (11), 228 (5), 210 (50), 184 (11), 84 (22); HRMS (CI) C19H24N2O2S [M+] requires 
344.15585, found 344.15572. 
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N,N-diethyl-2-oxo-phenylethanesulfonamide 370 
 
 
To a stirring solution of N-methylaniline (0.03 mL, 0.27 mmol) in anhydrous 
tetrahydrofuran (5 mL) cooled to −78 °C, nButyl Lithium (2.5M in hexanes, 0.12 mL, 
0.30 mmol) was added dropwise and stirred for 10 mins.  A solution of 
alkynylsulfonamide 197 (0.07 g, 0.30 mmol) in anhydrous tetrahydrofuran (2 mL) was 
added dropwise and the resulting reaction mixture was stirred at −78 °C for 2 h and at 
room temperature for a further 30 min.  The solution was partitioned between water (10 
mL) and dichloromethane (10 mL) and the aqueous layer extracted with 
dichloromethane (2 x 10 mL).  The combined organic layers were washed with brine 
(10 mL), dried (MgSO4), filtered and concentrated in vacuo to afford the crude product, 
which was purified via column chromatography (10-30% diethyl ether:petroleum ether) 
to afford the title compound (0.009 g, 11%) as a colourless oil; IR νmax/cm-1 (film) 
2977, 2939, 1675, 1589, 1442, 1335, 1270, 1151, 1021; 1H NMR (CDCl3, 600 MHz, 
ppm) δH 8.05 (2H, d, J = 7.3 Hz, ArH), 7.63 (1H, t, J = 7.3 Hz, ArH), 7.51 (2H, t, J = 
7.1 Hz, ArH), 4.57 (2H, s, CH2), 3.29 (4H, q, J = 7.2 Hz, N(CH2CH3)2), 1.20 (6H, t, J = 
7.2 Hz, N(CH2CH3)2); 13C NMR (CDCl3, 150 MHz, ppm) δC 188.2 (s), 136.4 (s), 134.1 
(d), 128.9 (d), 58.1 (t), 43.3 (t), 14.1 (q).  Data consistent with literature values.209 
 
General Method for methylation of anilines 
 
To a stirring suspension of acetonitrile (1 mL) and potassium carbonate (1.2 mmol) at 0 
°C, aniline (1 mmol) was added dropwise, followed by the dropwise addition of methyl 
iodide (3 mmol).  The resulting suspension was allowed to stir at room temperature for 
between 10-30 mins, before the dropwise addition of 2M HCl(aq).  The resulting mixture 
was extracted with diethyl ether (3 x 20 mL) and the combined organic layers were 
washed with water (2 x 20 mL).  After removal of the solvent, column chromatography 
was used to afford the title compound. 
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N-Methylquinolin-8-amine 381 
 
 
 
8-Aminoquinone. Colourless oil (0.16 g, 15%); 1H NMR (CDCl3, 600 MHz, ppm) δH 
8.71 (1H, dd, J = 4.2 & 1.6 Hz, ArH), 8.07 (1H, d, J = 8.3 Hz, ArH), 7.42 (1H, t, J = 7.8 
Hz, ArH), 7.38 (1H, dd, J = 8.3 & 4.2 Hz, ArH), 7.05 (1H, d, J = 7.8 Hz, ArH), 3.05 
(3H, s, CH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 146.7 (d), 145.8 (s), 136.4 (d), 
128.7 (s), 128.1 (d), 121.5 (d), 113.8 (d), 104.4 (d), 30.2 (q). Data consistent with 
literature values.210  
 
2-Methyoxy-N-methylaniline 382 
 
 
 
o-Anisidine. Colourless oil (0.15 g, 17%); 1H NMR (CDCl3, 600 MHz, ppm) δH 7.11 
(1H, d, J = 7.9 Hz, ArH), 6.29 (1H, dd, J = 8.3 & 2.2 Hz, ArH), 6.25 (1H, dd, J = 8.3 & 
2.2 Hz, ArH), 6.18 (1H, t, J = 2.2 Hz, ArH), 3.78 (3H, s, OCH3), 2.83 (3H, s, NCH3); 
13C NMR (CDCl3, 150 MHz, ppm) δC 160.9 (s), 150.7 (s), 130.0 (d), 105.9 (d), 102.6 
(s), 98.5 (d), 55.3 (q), 33.9 (q). Data consistent with literature values.211  
 
Ethyl 4-(methylamino)benzoate 383 
 
 
 
Benzocaine. Yellow solid (0.13 g, 31%) mp. 65-66 °C (literature222 value 66-67 °C); 1H 
NMR (CDCl3, 600 MHz, ppm) δH 7.88 (2H, d, J = 8.8 Hz, ArH), 6.55 (2H, d, J = 8.8 
Hz, ArH), 4.31 (2H, q, J = 7.3 Hz, OCH2CH3), 2.90 (3H, s, NCH3), 1.36 (3H, t, J = 7.3 
N
NH
NH
OMe
NH
CO2Et
4.   Experimental
 
  122 
Hz, OCH2CH3); 13C NMR (CDCl3, 150 MHz, ppm) δC 167.0 (s), 131.7 (t), 131.3 (s), 
118.7 (s), 111.2 (t), 77.3 (t), 60.3 (q), 14.2(q). Data consistent with literature values.210  
 
4-Methylaminonitrobenzene 384 
 
 
 
4-Nitroaniline. Yellow oil (0.12 g, 27%); 1H NMR (CDCl3, 600 MHz, ppm) δH 8.11 
(2H, d, J = 9.2 Hz, ArH), 6.53 (2H, d, J = 9.2 Hz, ArH), 2.94 (3H, s, CH3); 13C NMR 
(CDCl3, 150 MHz, ppm) δC 138.3 (s), 154.2 (s), 126.5 (d), 110.8 (d), 30.3 (q). Data 
consistent with literature values.212  
 
NH
NO2
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